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ABSTRACT 
BACKGROUND 
Haematopoietic stem cell transplantation remains the only curative 
option for many haematological malignancies. Currently, the majority of 
procedures for procurement of haematopoietic progenitor cells are 
performed by peripheral blood apheresis collection. The development of 
apheresis technology, the discovery of haematopoietic growth factors and 
small molecule CXCR4 antagonist for stem- cell mobilization and in vivo 
experimental transplantation studies that eventually led to clinical PBSCT. 
The quality of PBSC graft be assessed by its speed of engraftment. 
The advantage of early engraftment of haematopoietic stem cell 
transplantation include, reduced incidence of post transplant neutropenia 
associated infections, mortality, morbidity and shorten the length of 
hospital stay that eventually reduce the overall cost. 
Furthermore this valuable expensive procedure will be available for 
more number of patients who are waiting for their disease to be cured. This 
prospective observational study was undertaken to study (favorable and 
unfavorable) factors influencing the HSC engraftment.  
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AIM 
To find out the factors that influence (favorable or unfavorable) 
engraftmentof haematopoietic stem cell transplantation.  
METHODS 
During the study period all patients who underwent HSCT procedure 
for hematological malignancies was included and the related factors were 
obtained. The relative speed of engraftment was analyzed depending on the 
median and range of values (neutrophil and platelet engraftment days) 
obtained under each individual factors. 
RESULTS 
In our study there was a definite correlation between CD34+ cell 
dose and speed of engraftment. CD 34 + cell dose of˃ 2.5 × 106 cells/kg, 
achieved faster neutrophil and platelet engraftment. CD 34+ cell dose of 
<2.5x106 cells/kg achieveddelayedneutrophil and platelet engraftment 
Autologous PBSCT showed faster engraftment than allogenic 
PBSCT. The expected speed of engraftment could be achieved with higher 
dose of CD34+ cells even in patients with partial HLA match. Among 
various hematological malignancies multiple myeloma patients showed 
relatively rapid engraftment with autologous PBSC as a source. Total Body 
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irradiation and chemotherapeutic agent busalphan as a conditioning 
regimen showed relatively slower PBSCT engraftment.  
CONCLUSION 
Since early engraftment reduces length of hospital stay, morbidity, 
mortality and cost of this highly expensive treatment, it is imperative to 
utilize all available options to enhance the speed of engraftment. In a 
country like India where there are a few established haematopoietic stem 
cell transplantation centers available, there are many patients desperately 
waiting for their life to be saved by this specialized procedure. Hence, 
successful and faster PBSC graft engraftment is absolutely essential.  
 
[Key words: Peripheral Blood Stem Cell Transplant (PBSCT), Peripheral 
Blood Stem Cell (PBSC), Haematopoietic Stem Cell (HSC), Human 
Leukocyte Antigen( HLA)] 
------------------- 
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LIST OF ABBREVIATIONS 
 
AABB - American Association of Blood Bank  
ANC - Absolute Neutophil Count 
ALL  - Acute Lymphocytic Leukemia 
AML - Acute Myeloid Leukemia 
BM  - Bone Marrow 
Bu Cy - Busalphan and Cyclophosphamide 
BCNU - Carmustin 
Bu Flu - Busalphan and Flucytocin 
Bu Cy Flu - Busalphan, Cyclophosphamideand Flucytocin 
CXCR4 - Chemokine (C-X-C) Motif Receptor 4 
CFU-GM - Granulocyte Macrophage Colony Forming Unit 
cGY  - Centigrey 
CBV -         Cyclophosphamide, BCNU(Carmustin), VP16(Etoposide) 
Cy TBI - Cyclophosphamide and Total Body Irradiation 
CLL  - Chronic Lymphocytic Leukemia 
CML - Chronic Myelogenous Leukemia  
CMV - Cytomegalovirus 
DMSO - Dimethyl Sulfoxide 
EPO  - Erythropoietin 
Flt 3  - FMS Like Tyrosine Kinase-3 
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G-CSF - Granulocyte- Colony Stimulating Factor 
GM-CSF - Granulocyte Macrophage- Colony Stimulating Factor 
GY  - Grey   
HSC  - Haematopoietic Stem Cell 
HSCT - Haematopoietic Stem Cell Transplant 
HLA - Human Leukocyte Antigen 
HPC(A) - Haematopoietic Progenitor Cell Apheresis 
HPC(C) - Haematopoietic Progenitor Cell Cord 
HPC(M) - Haematopoietic Progenitor Cell Marrow 
HSV  - Herpes Simplex virus 
HIV  - Human Immuno Deficiency Virus 
HL  - Hodgkin Lymphoma 
ICM  - Inner Cell Mass 
iPSCs - Induced Pluripotent Stem Cells 
IL3  - Interleukin 3 
ISHAG - International Society of Hematotherapy and Graft  
Engineering 
LVL  - Large Volume Leukapheresis 
LACE - Lomustine, Adriamycine, Cyclophosphamide, Etoposide 
MNCs - Mono Nuclear Cells 
MMP-9 - Matrix Metallo Protinase 9 
MM  - Multiple Myeloma 
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NVL - Normal Volume Leukapheresis 
NHL - Non Hodgkin Lymphoma 
PBSC - Peripheral Blood Stem Cell 
PBSCT - Peripheral Blood Stem Cell Transplant 
PCD  - Plasma Cell Disorder 
PCR  - Polymerase Chain Reaction  
SSCs - Somatic Stem Cells 
SDF-1 - Stromal cell Derived Factor 
SCID - Severe Combined Immuno Deficiency 
TPO  - Thrombopoietin 
VCAM - Vascular Cell Adhesion Molecule 
VLA 4 - Very Late Antigen 4 (Integrin Alpha 4 Beta 1) 
VDRL - Venereal Disease Research Laboratory 
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ABSTRACT 
BACKGROUND 
Haematopoietic stem cell transplantation remains the only curative 
option for many haematological malignancies. Currently, the majority of 
procedures for procurement of haematopoietic progenitor cells are 
performed by peripheral blood apheresis collection. The development of 
apheresis technology, the discovery of haematopoietic growth factors and 
small molecule CXCR4 antagonist for stem- cell mobilization and in vivo 
experimental transplantation studies that eventually led to clinical PBSCT. 
The quality of PBSC graft be assessed by its speed of engraftment. 
The advantage of early engraftment of haematopoietic stem cell 
transplantation include, reduced incidence of post transplant neutropenia 
associated infections, mortality, morbidity and shorten the length of 
hospital stay that eventually reduce the overall cost. 
Furthermore this valuable expensive procedure will be available for 
more number of patients who are waiting for their disease to be cured. This 
prospective observational study was undertaken to study (favorable and 
unfavorable) factors influencing the HSC engraftment.  
 
AIM 
To find out the factors that influence (favorable or unfavorable) 
engraftmentof haematopoietic stem cell transplantation.  
METHODS 
During the study period all patients who underwent HSCT procedure 
for hematological malignancies was included and the related factors were 
obtained. The relative speed of engraftment was analyzed depending on the 
median and range of values (neutrophil and platelet engraftment days) 
obtained under each individual factors. 
RESULTS 
In our study there was a definite correlation between CD34+ cell 
dose and speed of engraftment. CD 34 + cell dose of˃ 2.5 × 106 cells/kg, 
achieved faster neutrophil and platelet engraftment. CD 34+ cell dose of 
<2.5x106 cells/kg achieveddelayedneutrophil and platelet engraftment 
Autologous PBSCT showed faster engraftment than allogenic 
PBSCT. The expected speed of engraftment could be achieved with higher 
dose of CD34+ cells even in patients with partial HLA match. Among 
various hematological malignancies multiple myeloma patients showed 
relatively rapid engraftment with autologous PBSC as a source. Total Body 
irradiation and chemotherapeutic agent busalphan as a conditioning 
regimen showed relatively slower PBSCT engraftment.  
CONCLUSION 
Since early engraftment reduces length of hospital stay, morbidity, 
mortality and cost of this highly expensive treatment, it is imperative to 
utilize all available options to enhance the speed of engraftment. In a 
country like India where there are a few established haematopoietic stem 
cell transplantation centers available, there are many patients desperately 
waiting for their life to be saved by this specialized procedure. Hence, 
successful and faster PBSC graft engraftment is absolutely essential.  
 
[Key words: Peripheral Blood Stem Cell Transplant (PBSCT), Peripheral 
Blood Stem Cell (PBSC), Haematopoietic Stem Cell (HSC), Human 
Leukocyte Antigen( HLA)] 
------------------- 
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INTRODUCTION 
Haematopoietic stem cell (HSC) transplantation remains the only 
curative option for many haematopoietic malignancies. The pluripotent 
haematopoietic stem cells required for this procedure are usually obtained 
from the bone marrow or peripheral blood. Currently, the majority of 
procedures for procurement of haematopoietic progenitor cells are 
performed by peripheral blood apheresis collection.1 
After all the disappointment of clinical stem cell transplants in the 
late 1950’s and early 1960’s there was general distrust about the field, 
nevertheless improvements in transfusion medicine and understanding of 
HLA typing encouraged the clinical application of  stem cell 
transplantation.2 
Since then, more patients received haematopoietic stem cell 
transplantation to treat life threatening malignant and nonmalignant diseases 
and observational outcome research studies were carried out worldwide to 
address the important issues in haematopoietic stem cells transplantation.2 
The first successful transplantations of allogenic haematopoietic 
stem cells were performed in 1968 in three children with congenital immune 
deficiency diseases. In each instance, haematopoietic cells were collected 
from the bone marrow of sibling donors who were genotypically identical to 
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the recipient for human leukocyte antigens (HLAs). Since then, more than 
800,000 patients have received haematopoietic cell transplantations 
(HSCTs) to treat life-threatening malignant and non-malignant diseases.3 
Current estimates of annual number of HSCTs are 55,000–60,000, 
worldwide. Reasons for widespread use include proven and potential 
efficacy in many diseases, better understanding of the appropriate timing of 
harvest, greater ease of haematopoietic progenitor cell collection by 
apheresis, patient selection, greater availability of donors, improved 
transplantation strategies and supportive care, leading to less transplantation 
related morbidity and mortality and an increased ability to perform the 
procedure in older and sicker patients.4 
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AIM 
To study the factors influencing the engraftment of haematopoietic 
stem cell transplantation in patients with hematological malignancy. 
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REVIEW OF LITERATURE 
STEM CELLS 5 
Stem cells are unspecialised cells capable of renewing themselves 
through cell division, under certain physiologic or experimental conditions 
after long period of inactivity they can be induced to become tissue or organ 
specific cells with special functions.  
1. Embryonic Stem Cells  
Embryonic stem cells are totipotent or pluripotent in nature. Those 
derived from pre-implantation embryo (morula stage) which is derived from 
embryos before differentiation of trophoectoderm and inner cell mass, 
capable of giving rise to the entire organism and extra embryonic tissues are 
totipotent. 
Those derived from the inner cell mass (ICM) are pluripotent, 
having ability to differentiate into derivatives of all three germ layers, 
(ectoderm, mesoderm and endoderm), except placenta.  
Embryonic stem cells can also be generated by reprogramming of 
somatic cells, giving rise to induced pluripotent stem cells (iPSCs). Induced 
pluripotent stem cells (iPSCs), are pluripotent in nature, similar to the 
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embryonic stem cells they are capable of indefinite expansion and 
differentiation into ectodermal, mesodermal and endodermal cells.  
These cells can be generated from somatic cells by a variety of 
genetic and epigenetic methods. 
2. Somatic Stem Cells (SSCs) 
Somatic stem cells (SSCs) are a resident, self-renewable population 
of cells which are present in virtually all organs and tissues of the body. 
They have limited differentiation capacity and may be multipotent or 
unipotent. They are essentially undifferentiated, resident in differentiated 
tissues and are committed to the lineage of that organ. They may, however, 
have limited plasticity.  
Haematopoietic progenitor cells and haematopoietic stem cells are 
somatic stem cells (SSCs) used for haematopoietic reconstitution after 
myeloablative therapy. 
Source of haematopoietic stem cells  
1. Bone Marrow6 
Healthy adult bone marrow contains 0.5-1% CD34+ cells. Bone 
marrow harvesting is a surgical procedure performed in an operating room 
under the general or regional anesthesia.  
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The marrow is aspirated 3to10 ml at a time from multiple punctures 
of both posterior iliac crests, using specially designed stainless steel beveled 
needles and syringes. 
Optimal post transplantation haematopoietic recovery needs 2 to 
5×106 CD 34 Cells/ kg or 2to5×108 total nucleated cells/kg recipient body 
weight. To achieve this optimal dose, require 1 to 1.5 litre marrow collection 
for an adult allogenic recipient. In case of allogeneic donors harvested for 
the Be The Match Registry maximum of 20 mL/kg donor weight marrow 
will be collected. 36aabb 
2. Umbilical or Placental Cord Blood Collection7 
Cord blood collection can either be performed by the obstetrician 
with the placenta in situ, or immediately after delivery by a trained team. 
The usual volume collected is less than 170 ml with anticoagulant, usually 
ACD formula A (ACD-A) or citrate-phosphate-dextrose- adenine (CPDA-1) 
3. Haematopoietic Stem Cell Collection by Apheresis8 
The peripheral blood of healthy adults contain less than 0.1% 
HSCs, this number increases during recovery from cytotoxic therapy and 
even more when mobilising factors such as G-CSF are administered.  
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The donor stimulated with haematopoietic growth factors, or 
chemotherapy and growth factors, a sufficient number of circulating stem 
cells for marrow rescue collected in one to three apheresis procedures. Peak 
counts usually obtained at the end of 5 days after stimulation with G-CSF 
(10 to 20 μg/kg/day) or 10 to 14 days after chemotherapy and G-CSF. 
Leukapheresis started when the peripheral CD34 count reaches or exceeds 
10 CD34+cells/ μL. 
The apheresis device uses a centrifuge to separate and collect 
MNCs, including peripheral blood HSCs, from the blood. In order to achieve 
a target cell dose of 2 to 5 ×106 CD34+ cells/kg it is necessary to process 12 
to 25 liters of blood or 2.5 to 6.0 times the patient’s calculated blood 
volume.  
Instrument settings such as inlet flow rate, centrifuge speed, collect 
pump flow rate and anticoagulant: whole blood ratio vary depending on the 
target cell type to be collected. 
Comparison of Peripheral Blood and Marrow as Haematopoietic 
Sources 
Collection of PBPCs rather than marrow eliminated the need for 
general anesthesia, an operating room and the repeated insertion of marrow 
aspiration needles into the posterior iliac crest and free of tumor cells in a 
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patient with marrow metastases and opportunity to receive potentially 
curative marrow ablative therapy.9 
Advantages of Peripheral Blood Stem Cell Collection (PBPCs) by 
Apheresis 
Various studies suggest PBPCs as the preferred source of 
haematopoietic cells for both autologous and allogeneic transplantation. 
PBPCs are advantageous for the recipient, because the recovery 
(engraftment) of platelet and white cell counts following either autologous 
or allogenic PBPC transplantation is more rapid compared with recovery 
following transplantation of marrow cells.10-13 
The stem cell mobilization techniques can increase the number of 
circulating progenitor cells and allow adequate collection of stem cells with 
minimum number of leukapheresis. PBPCs offer the potential advantage of 
containing fewer contaminating tumour cells than marrow. Presence of 
tumor cells in the collected marrow is an exclusion criterion for autologous 
marrow transplantation.14-17 
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Mobilization of Peripheral Blood Progenitor or Stem Cells 
Biology of Haematopoietic Progenitor or Stem Cell Mobilization 
Cottler-Fox et al in their study stated that haematopoietic stem cells 
are cells capable of self-renewal and differentiation into all blood cell 
lineages. In sufficient numbers, they give rise to complete sustained 
haematopoietic engraftment. In contrast, haematopoietic progenitor cells are 
committed to a blood cell lineage. They do not have the capacity for 
sustained self-renewal or the ability to differentiate into all haematopoietic 
lineages.18 
Papayannopoulou T reported that the HPC adherence to the 
haematopoietic niche is mediated by a variety of adhesion molecule 
interactions, including the binding of a receptor, CXCR4 on HPCs, to 
stromal- cell-derived factor 1 (SDF1) the binding of beta-1 integrin adhesion 
molecules (VLA4 on HPCs) to vascular cell adhesion molecule 1 (VCAM1) 
on stromal cells and to fibronectin and the binding of HPC CD44 to 
hyaluronic acid, among others.19 (Fig.1) 
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(Fig.1) Haematopoietic “Niche” 
Yin T et al and Papayannopoulou T showed that the HPC 
mobilization stimulated by myelosuppressive chemotherapy or by 
administration of haematopoietic growth factors leads to temporary increase 
in the dissociation rate of HPCs from the niche through the disruption of 
those adhesive interactions and the migration of HPCs into the marrow and 
then into the peripheral blood circulation. 19,20 
The mobilising regimens are associated with the release of 
metalloproteases like MMP9, elastase, and cathepsin G which cleave one or 
more receptor-ligand pairs like SDF1 and release HPC from their stroma.18,19 
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In contrast, agents or antibodies those directly disrupt or block 
HPCs or stromal adhesive receptors such as VLA4 antibodies, or 
oligopeptides that block CXCR4, are associated high mobilisation of 
circulating HPCs in a matter of minutes to hours.18 
Factors reported to affect HPC mobilization include the patient’s 
age and gender, the presence of marrow disease, the extent and the type of 
prior myelotoxic therapy like cancer chemotherapy, radiotherapy or 
treatment of hepatitis C virus with interferon-γ and the dose, schedule, type 
of mobilizing regimen used and the patient’s underlying disease, patient’s 
genetic polymorphisms.18,21-23 
Mobilization198 
Approximately 0.03% to 0.05% of the white blood cells (WBCs) in 
the peripheral blood of normal healthy individuals express CD34 for a total 
of 0 to 5 CD34+ cells per μL of blood. In the marrow, 3% to 5% of cells 
express CD34 positivity. 
The rationale for mobilization is to minimize the number of 
apheresis procedures needed to obtain enough stem and progenitor cells for 
successful  post transplant engraftment of the absolute neutrophil  count 
(ANC) to 500/μL and of the platelet count to 20,000/μL without platelet 
support. 
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Yin T et al in their study found that in the absence of mobilization, 
8 to 14 apheresis procedures on separate days were required to obtain a yield 
of stem and progenitor cells adequate for transplantation (a median of 8.4 × 
108 mononuclear cells (MNCs)/kg.  With current mobilization methods, up 
to three apheresis procedures are needed to obtain a yield of stem and 
progenitor cells for adequate for engraftment.24 
PBPC Collection during Steady-State Hematopoiesis199 
Autologous PBPCs provided reliable, sustained haematopoietic 
recovery when transplanted, but the paucity of such cells in the circulation 
necessitated six to eight or more apheresis procedures to collect an 
acceptable graft product. While this large number of collections from a 
single patient is feasible, it is also cumbersome and time-consuming and 
discouraged PBPC transplantation except for very specific indications. 
However, when the number of progenitors and stem cells in the 
circulation are deliberately increased, the number of collections is reduced, 
making the use of PBPCs more acceptable. 
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Haematopoietic Cytokines Used in Mobilisation and Its Effect on 
Engraftment 
Chao N in their study concluded that the time to reach an ANC of 
500/μL and a platelet count of 20,000/μL is significantly shorter with 
cytokine-mobilized PBPCs than with immobilised PBPCs.25 
Nemunaitis J et al showed stem and progenitor cells mobilized by 
exogenous haematopoietic growth factors, currently, G-CSF (filgrastim) and 
GM-CSF (sargramostim) are the cytokines most commonly used for 
mobilization, which were used initially to accelerate recovery of the ANC 
after chemotherapy.26 
1. G-CSF 
Granulocyte Colony-Stimulating Factor (G-CSF) is a 177-amino 
acid protein of approximately25 kDa. Lane TA et al found G-CSF is more 
potent as a mobilizing agent and is far more widely used than GM-CSF, 
which is typically used in combination regimens. G-CSF administration to 
normal or autologous donor’s results in dose-dependent increase in 
leukocyte, lymphocyte, and HPC counts.27,28 
Weaver CH et al stated that G-CSF is typically administered once 
daily subcutaneously in doses ranging from 5 to 20 μg/kg/day, although 
higher doses may be used in poor mobilizers.29 Kroger N et al suggest that 
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divided doses of G-CSF permit higher doses, result in improved 
mobilization with fewer side effects, or both, but those findings are not 
universal.30 
Watts MJ in their study showed that, when used alone, G CSF is 
ideally administered at least 4 hours before scheduled HPC collection 
because of a transient decrease in HPC levels that occurs shortly after G-
CSF administration.31 
A single dose of long-acting, pegylated G-CSF has been reported to 
result in satisfactory allogeneic or autologous donor HPC mobilization, but 
this drug is not currently approved for HPC mobilization.32 
Sato N, Sawada K, Takahashi A, et al in their study showed that in 
healthy individuals, G-CSF at 2 μg/kg/day induced maximal CFU-GM 
approximately 24 to 30 hours after five daily injections, with the peak level 
maintained for approximately 24 hours.33 Grigg AP et al found that G-CSF 
at 10 μg/kg/day induced a median increase of 157-fold in circulating CFU-
GM(range = 52-3940) and a 22-fold increase in circulating CD34+ cells 
(range = 8-105).34 
Similarly Korbling M et al found that a 16-fold increase in 
circulatingCD34+ cells,35 and Tjonnfjord GE et al found that a peak 
peripheral bloodCD34+ cell count on day 4 or 5 of 20 to 100CD34+ cells/μL 
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peripheral blood,36 with wide inter individual variation after G-CSF 
mobilization. 
At present, a widely used and effective mobilization protocol for 
allogeneic donors is 5 days of G-CSF (5-12 μg/kg/day subcutaneously) 
followed by 2 days of leukapheresis for collection of stem and progenitor 
cells10 
Anderlini P, Korbling M, Dale D et al in their study found that 
when used in normal donors, G-CSF doses >10 μg/kg/day are of uncertain 
benefit and are associated with increased side effects. Most centers avoid 
leukocyte counts >70,000/μL by dose reduction if desirable before apheresis, 
especially for normal allogeneic donors.37 
2. GM-CSF 
Haas R, Ho AD, Bredthauer U et al in their study showed heavily 
pre-treated patients who were ineligible for marrow transplantation, 
continuous IV GM-CSF infusion induced a median 8.5-fold increase in 
circulating CFU-GM that allowed collection of adequate numbers of PBPCs 
for transplantation.38,39 
With subcutaneous injection, there is a dose-dependent increase in 
CFU-GM, with a maximal effect at 10 μg/kg/day. Recommended doses of 
GM-CSF range from 3.0 to 10.0 μg/kg/day.40 
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3. G-CSF versus GM-CSF 
Bolwell B, Goormastic M, Yanssens T et al studied on 44 patients 
with lymphoma received both marrow and PBPCs included random 
assignment to G-CSF or GM-CSF mobilization. The patients who received 
G-CSF achieved an ANC of 500/ μL and a platelet count of 20,000/μL after 
mean intervals of 9 and 13 days, respectively and for the patients who 
received GM-CSF, the intervals were 14 and 18 days, respectively.9 
Capillary leak syndrome, including pericarditis and fluid retention, 
is a dose-limiting toxic effect of GM-CSF. Rare side effects of G-CSF 
include splenic rupture, iritis, cardiac ischemia, capillary leak syndrome, and 
gouty arthritis. 41 
Takaue Yet al and Lane T A et al found that improved mobilization 
of PBPCs can be achieved with combinations of haematopoietic cytokines. 
G-CSF and GM-CSF together stimulate more proliferation of immature cells 
than either cytokine alone both in vitro and in vivo.42,43 
4. Adhesion-blocking agents and cytokines( Plerixafor /AMD3100) 
DiPersio JF et al and DiPersio JF et al showed that Mozobil 
(AMD3100) was recently approved for use in combination with G-CSF for 
the mobilization of CD34+ cells in autologous transplant patients with 
multiple myeloma.44 
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Mozobil is a synthetic SDF1-like molecule that blocks the adhesive 
interaction between SDF1 on marrow stromal cells and CXCR4 on CD34+ 
cells. It is unique among clinical CD34+ cell mobilizing agents in that it 
stimulates the release of CD34+ cells within several hours after 
administration. Mozobil additive effects increase circulating CD34+ cells 
and T cells when it is administered in combination with G-CSF or 
myelosuppressive agents.10 
DiPersio JF et al stated that the FDA approved protocol for HPC 
mobilization using Mozobil and G-CSF combined, calls for 10 μg/kg G-CSF 
to be administered each morning and for 0.24 mg/kg Mozobil to be 
administered subcutaneously (in patients with normal renal function) on day 
4 of G-CSF mobilization, approximately 11 hours before leukapheresis.10 
DiPersio  JF et al and DiPersio JF et al showed that the combined 
use of G-CSF and Mozobil has been reported to increase the number of 
HPCs collected per apheresis procedure, to decrease the number of apheresis 
procedures required to collect a target dose of HPCs, and to improve the 
mobilization of HPCs in poor mobilizers.44,10 
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5.  Flt3 Ligand11 
Rusten LS et al showed that the cytokine Flt3 ligand, which binds 
to a tyrosine kinase receptor on the surface of stem and progenitor cells 
mobilizes them effectively.  
Flt3 ligand is synergistic with SCF, G-CSF, GM-CSF, and IL-3 in 
vitro, producing 20-fold, 1.6-fold, 3.4-fold, and3.8-fold enhancements of 
CFU-GM, respectively. 
6. Stem Cell Factor (SCF)  
Nemunaitis J in his study on recombinant SCF revealed a mast-cell-
related dose-limiting effect. Patients must therefore be pre medicated with 
antihistamines, albuterol, and/or pseudoephedrine before SCF is 
administered.12 
There was a significant reduction (p <0.05) in the number of 
collections required to reach target yields for patients receiving SCF plus G-
CSF compared with patients receiving G-CSF alone; however, PBPCs 
collected with G-CSF alone engrafted equally rapidly.13 
7.  IL-3  
The group receiving simultaneousIL-3 and G-CSF required four 
procedures and those patients receiving only IL-3required six procedures.45 
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Several additional agents that support HPC mobilization have been 
described, such as dextran, human growth factor, interleukin-8, 
erythropoietin (EPO) and  thrombopoietin (TPO).  
Additional agents that induce haematopoietic stem cell mobilization 
by interfering with their adhesive properties to the niche are currently under 
investigation. 
Mobilization Using Chemotherapy 
Richman CM et al showed in the setting of autologous 
haematopoietic stem cell transplantation, mobilizing chemotherapy perform 
various roles, including 1) Treating the patient’s malignancy 2) Testing the 
sensitivity of the tumor to cytotoxic therapy 3) Mobilizing stem cells.46 
Testa U et al showed that the mechanism of action 
chemotherapeutic agents mobilize stem cells is by endogenous production of 
haematopoietic cytokines in response to their action on dividing cells. Serum 
concentrations of interleukin-3 (IL-3), granulocyte colony-stimulating factor 
(G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-
6, IL-8, thrombopoietin, and Fms-like tyrosine kinase 3 (Flt3) ligand, all 
increase 2 to 6 days after chemotherapy.47 
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A possible advantage of some disease specific chemotherapy-based 
regimens is the potential for “in-vivo purging” of tumor cells that might 
otherwise contaminate the HPC (A) product  and/or the ability to keep 
rapidly progressive disease in check during the time required to mobilize and 
collect HPC and to prepare the patient for the high-dose anti 
neoplastictherapy.48 
Mobilization Using Both Chemotherapy and Growth Factors 
The combination of chemotherapy and cytokines is the most 
effective and commonly employed mobilization protocol in the autologous 
setting. Circulating progenitors can be increased by 100- to 160-fold, which 
is similar to the effect of cytokines alone in healthy allogeneic donors.49 
 Haas R, Hohaus S, Ehrhardt R et al have found that PBPCs 
mobilized by chemotherapy plus either G-CSF or GM-CSF gave faster 
engraftment than PBPCs induced by chemotherapy alone. The most 
common regimens include chemotherapy followed by daily G-CSF 
throughout the PBPC collection period.14 
Oliver Rick et al in their study found that chemotherapy 
(paclitaxel,ifosfamide) + G-CCF mobilised CD34+ cells showed  increased 
mobilisation and  single 500 mg amifostine before chemotherapy also  
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increase the CD34+ cell counts on days 10 and 11without improving the 
overall PBPC collection result.50 
Haas R, Hohaus S, Egerer G et al in their study reported that as with 
chemotherapy-alone regimens, combined modality regimens have the 
potential to result in chemotherapy-induced cytopenia, the frequency of 
which varies depending on the intensity of the chemotherapy regimen and on 
the patient’s marrow reserve. Also, the administration of growth factor in 
combination with chemotherapy may diminish the duration of neutropenia.15 
One widely used combined modality regimen (cyclophosphamide 
plus G-CSF) results in predictable mobilization with few side effects. The 
combination of Mozobil after chemotherapy with or without G-CSF has also 
been reported to further enhance HPC mobilization.16 
Poor Mobilizers 
Anderlini P et alin their study found that poor HPC mobilization 
(2% to 20% of mobilization attempts) is defined as the failure to achieve a 
minimum level of 5 to 20 CD34+ cells/μL in peripheral blood after 
completion of the mobilization regimen, or as the inability to collect at least 
1 to 2 × 106 CD34+ cells/kg during a single apheresis procedure, or as the 
failure to collect a total of 5 × 106 CD34+ cells/ kg in all collections.17,51 
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Ewing JC et al  indicate that the management of patients who fail to 
mobilize will remains a challenging problem and is a common reason that 
otherwise eligible patients do not receive an autologous transplant42. Pavone 
V et al found this is because patients transplanted with low doses of HPCs 
have prolonged times to engraftment, higher rates of graft failure and post 
transplant complications and poorer outcomes.52 
Cottler-Fox M, Lapidot T indicate that factors such as the 
premobilization peripheral blood CD34+ cell count, flt3 ligand level or 
platelet count, have been reported to correlate with and to predict 
postmobilization CD34+ cell counts.53 
Micallef IN et al and Calandra G et al indicate that either adding 
mozobil on day 4 for myeloma / lymphoma patients who are poorly 
mobilizing with G-CSF or remobilizing with growth factor, Mozobil are 
effective in most myeloma and non-Hodgkin lymphoma patients who 
mobilize poorly.54,55-59 
Gazitt Y et al reported that the immediate administration of 32 
μg/kg/day of G-CSF for 4 days led to acceptable mobilization in 80% of a 
heterogeneous group of poorly mobilizing autologous patients. 56 
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Cassens U et al found that Large-volume leukapheresis, in which 
four to six patient blood volumes are processed, may also improve overall 
HPC collection in those patients.57 
Lemoli RM et al found that the transplantation of autologous 
HPC(M) collected after marrow harvesting in poor HPC(A) mobilizers was 
also reported to enable marrow transplantation, even though with variable 
rates of engraftment speed.58 
        Factors Reported to Affect the Mobilization of HPC, 
Mobilization method 
Chemotherapy (Degree of transient 
myelosuppression) 
Growth factors (Type, schedule, dose) 
Combined chemotherapy and growth factors 
Extent and type of prior chemotherapy, 
radiotherapy  
Drugs (interferon-γ ,lenalidomide) 
Patient or donor age 
Patient or donor diagnosis 
Patient or donor gender 
Presence of marrow disease or metastases 
 
COLLECTION OF PERIPHERAL BLOOD STEM CELLS 
Collection of Stem Cells 
Collection of PBPCs is performed by apheresis instruments. The 
blood cells sediments into distinct layers according to their molecular weight 
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when anticoagulated whole blood is subjected to centrifugal force. The 
apheresis instrument harvests the mono nuclear cells (MNCs) in the zone 
between the granulocyte layer and the platelet layer by a leukapheresis 
procedure. 
Collection Goal 
The HPC (A) collection goal range for allogeneic transplantation is 
similar to that for autologous transplantation (2 to 5 × 106 CD34+ cells/kg).60 
Instrument-Related Variations inCollection and Engraftment 
Dzieczkowski JS, McGonigal M, Cook J et al in their study found 
that all apheresis instruments that can collect WBCs can also collect stem 
cells. None provides “better” stem cells in terms of faster haematopoietic 
reconstitution.61 
There are differences in the instruments and the products they 
collect. These include differences in extracorporeal volume, in the incidence 
of adverse effects, especially citrate reactions, in the degree of 
thrombocytopenia, and in flexibility to use anticoagulants other than citrate 
(such as heparin) in special circumstances such as for LVL or pediatric 
procedures.61 
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Ford DC, Pace N, Lehman C in their study found that the yield of 
CD34+ cells obtained from a collection depends, in part, on the efficiency of 
their collection, but other factors also have an influence. High WBC counts, 
haematocrit, and/or albumin concentrations can decrease collection 
efficiency.62 
Ford CD, Greenwood J, Strupp A, et al in their study found that a 
rapid decrease in blood CD34+ levels, not due to hemodilution, has been 
reported during the first 30 to 70 minutes of a procedure; this is followed by 
a relatively stable level for the remainder of the procedure.63 
Knudsen et al in their study showed that CD34+ cells and MNCs 
are recruited to the blood during PBPC collection, whereas granulocytes and 
platelets are not. Because recruitment is limited to the cell fraction being 
removed, a feedback mechanism may be responsible. CD34+ cells are most 
likely recruited from marrow or a marginal pool.There was no exhaustion of 
progenitor cell release and CD34+ cell recruitment was shown with several 
mobilization regimens. 64 
The clinical relevance of these findings is that the longer collection 
times will keep increasing the yield and will decrease the number of 
procedures needed to achieve the goal.  
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Ford CD et al measured CD34+ cell collection efficiency in 163 
consecutive donations with blood CD34+ cell levels >5/μL and found it to 
be significantly higher with the  Baxter CS3000.65 
Snyder EL et al in a clinical study evaluating collection efficiency, 
infusion toxicity, and engraftment characteristics, the Amicus was shown to 
be safe and effective for PBPC collection.66 
Timing of PBPC Collection  
Once it is decided to perform stem cell transplantation, it remains to 
be determined when during mobilization to begin apheresis and when to 
stop. Donor response to mobilization vary differently to based on age, 
amount of prior chemotherapy and/or radiotherapy, type of malignancy and 
degree of marrow involvement.  
The goal is to collect adequate PBPCs to give rapid, successful 
engraftment from the fewest apheresis procedures therefore scheduling the 
patients for apheresis in the autologous setting is more important. 
When to Start PBPC Collections  
Various criteria have been used to predict the optimal time to 
initiate collection of PBPCs. These include the absolute WBC count, the 
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kinetics of WBC recovery, the platelet count, and the blood level of CD34+ 
cells.67 
Haas R et al has been recommended that leukapheresis begin when 
the WBC count reaches 1000/μL. They also found that the blood CD34+ cell 
count is predictive of the total yield of progenitors and can also be used to 
determine when to initiate apheresis.68 
J.A. Perz-Simon et al in their study found that a minimum of 5 
CD34+ cells per µl in peripheral blood is enough to initiate leukapheresis.69 
Grigg AP, Roberts AW, Raunow H, et al,in their study have shown 
that for a 7-L collection using the Baxter CS3000 (Baxter Biotech, 
Deerfield, IL), a blood CD34+ cell count of 40 cells/μL predicted that the 
apheresis product would contain approximately 60 × 106 CFU-GM.70 
Similarly Fruehauf S et al have shown that the CD34+ cell content 
in the peripheral blood before mobilization correlates with the number of 
collections needed to obtain an adequate number of CD34+ cells.71 
Abba C. Zubair et al in their study showed that platelet (PLT) count 
before growth factor administration significantly correlated with total 
CD34+ cell yield in plasma cell disease patients who received prior 
chemotherapy. In addition, daily platelet count during PBPC harvest 
correlated with CD34+ cell yield for that day. 
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They suggest baseline platelet count is a sensitive indicator of 
autologous PBPC mobilization in PCD patients who received prior 
chemotherapy to determine the optimal period to mobilize treated PCD 
patients and to predict if enough cells can be collected for one or two 
transplants.72 
Cheolwon  Suh et al in their study found that initiation of peripheral 
blood progenitor cell harvest based on peripheral blood count of 5 CD34 
cells per mm3 after chemotherapy plus lenograstim mobilisation in the 
autologous setting showed that the median time for neutrophil engraftment  
was 10 days (95% confidence interval 9-11 days; range, 9-20 days) and the 
median time for platelet engraftment  was 12 days (95% confidence interval 
10-14 days; range, 7-27 days) and there were no cases of engraftment 
failure.73 
 L.Pierelli et al in their study found that accurate prediction of 
apheresis yield can be accurately calculated by formula with pre apheresis 
peripheral blood CD34 cell count and peripheral blood volume to be 
processed. 
CD34+cells per kg body weight collected = CD34+cells per ml of 
PB×(0.4)× (ml of peripheral blood processed per kg body weight).74 
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When to Stop Apheresis Collections 
Programs that lack such readily available cytometry services, 
especially after normal hours, an alternative method to assess apheresis 
yields is to measure the CD34+ cell content of the cells collected by 
apheresis approximately midway through the apheresis procedure and to 
extrapolate the final yield. 
When carefully used, that method has been reported to permit 
accurate decisions regarding whether to continue apheresis for another day 
or to discontinue it, without waiting for the final HPC (Apheresis derived) 
CD34+ cell count to be available. That approach may avoid unnecessary 
growth factor injections and apheresis procedures.75 
Leukapheresis for Second Autograft during Haematopoietic 
Engraftment of First Autograft 
N.Schwalla et al in their study concluded that (1) PBPC harvesting 
is feasible and well tolerated in the autologous setting. (2) In appropriate 
patients with efficient PBPC mobilization after conventional-dose 
chemotherapy, a further PBPC autograft can be collected during recovery of 
hematopoiesis after autologous blood progenitor cell transplantation, serving 
as a rescue for a second course of high dose chemotherapy.76 
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Harvest Schedules  
1. Standard Collections 
To obtain a predefined target yield, 1to 4 PBPC collections are 
needed. In a standard collection, 10 to 12 L of blood is usually processed in 
3 to 4 hours. Haas R, Mohle R, Fruhauf S et al in their study found that 
patients with poor-prognosis lymphoma were mobilized with chemotherapy 
plus G-CSF and collected when the WBC count exceeded 1000/μL. 68 
 Haas R et al also stated that the target yield of 2.5 × 106 CD34+ 
cells/kg was collected in a single 10-L leukapheresis in 34 of 61 patients. 
However 15 patients still had <2.5 × 106 CD34+ cells/kg after a median of 
six apheresis procedures. In case of poorly mobilized patients, 8 to 10 
procedures required to obtain an adequate yield of PBPCs. 68 
2. Large Volume Leukapheresis Increase the Stem Cell Mobilisation 
To minimize the number of collections, large volume leukapheresis 
(LVL) procedures were performed, in which 15 to 40 L of blood is 
processed over 6 to 8 hours, provides an adequate yield for many well 
mobilized patients. It is also be desirable for poorly mobilized patients to 
achieve the collection goal. 
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All patients experience a significant drop in platelet count and 
prolongation of partial thromboplastin time when 15 to 35 L of blood is 
processed.77 
Hillyer CD, Lackey DA III, Hart KK  et al in their study found that 
more CFU-GM were harvested from the final blood volume collected than 
from any of the first three blood volumes during recruitment of HPCs 
throughout the course of LVL.78 
Hillyer C, Tiegerman K, Berkman E et al also found that a 56% 
increase in the volume of blood processed (from 11.8 L to 18.5 L) lead to 
142% increase in the CFU-GM content of the apheresis product. Additional 
evidence supporting recruitment is that no difference was noted during LVL 
between the number of CD34+ cells/kg/liter in the first hour and the last 2 
hours.79 
Cassens U, Momkvist PH, Zuehlsdorf M et al in their study on 24 
patients undergoing LVL were compared with a control group of patients 
who were treated with G-CSF after mobilizing chemotherapy but did not 
undergo apheresis. 
 The LVL group experienced an increase in the relative yield during 
the second of six blood volumes processed but gradual decline of yield 
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thereafter. The timing of collection correlate well with peak blood CD34+ 
cell levels after G-CSF administration in the control patients.80 
Lack of recruitment is also supported by studies showing that the 
number of PBPCs steadily decreases during apheresis. Bojko et al found that 
the mean peripheral blood CD34+ cell count decreases from116/μL at the 
start of the procedure to 57/μL after four blood volumes are processed.81  
Prior Chemotherapy and Radiotherapy  
Aurlien E, HolteH, Pharo A, et al in their study on 141 heavily 
pretreated, relapsed lymphoma patients found that radiation, conventional 
chemotherapy  and high-dose chemotherapy all have a measurable negative 
impact on yields that may also influence engraftment kinetics.82 
In addition, even 6 months of treatment with alkylating agents 
significantly delayed engraftment and in extensively pretreated patients, the 
CD34+ cell yield required for rapid platelet engraftment increased from 2.0 
× 106/kg to 5.0 × 106/kg. 
However above study explained negative impact of prior therapy. 
The extensive prior therapy need not prevent successful PBPC collection in 
all cases. The authors attributed their success to the use of a particular 
mobilizing regimen (mitguazon, ifosfamide, methotrexate, and etoposide) 
and higher doses of G-CSF.82 
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Toward that goal, a host of chemotherapy regimens that are tailored 
to the patient’s malignant disease, most of which also use G-CSF or GM-
CSF to augment HPC mobilization, have been reported to have adverse 
effect on yield.83,84  
Impact of Disease State  
Has et al in their study found that no significant difference in PBPC 
yields between the relapsed and the patients in complete remission. 68 
Passos-Coelho J, Braine HG, Davis J et al in their study PBPC 
collection by single LVL found that neither complete nor partial remission 
had a significant impact on CD34+ cell yield.85 
Impact of Tumor Contamination86 
Relapse remains the primary cause of death in patients who receive 
autologous stem cell support after myeloablative chemotherapy. The 
question remains, however, whether tumor cells reinfused with PBPCs cause 
relapses or whether the disease was not eradicated by myeloablative therapy. 
Disease recurrence is typically found in previous disease sites, suggesting 
that chemotherapy was not curative. 
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 Rill DR et al in their gene-marking studies have demonstrated that 
the tumor cells reinfused with the PBPCs cause the relapse and these cells 
localize to sites where the original tumor is recurring.  
The probability of tumor contamination in PBPCs correlates with 
both disease stage and the occurrence of relapse. It therefore seems prudent 
to collect PBPCs during remission, when the total body tumor burden will be 
minimized. Similarly, autologous marrow transplantation is best performed 
when there is minimal tumor detectable in the marrow.  
Incidence of Tumor Contamination 
Tumor contamination of PBPC collections has been clearly 
demonstrated for both hematologic malignancies and solid tumors.87Using 
immunoglobulin gene rearrangement polymerase chain reaction (PCR), 
Stewart et al found a contamination rate of 82% in 47 myeloma patients.88 
McCann et al, also using PCR, detected tumor contamination in 
82% of the PBPC collections from patients with relapsed non-Hodgkin’s 
lymphoma.89 
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The Impact of Relapse and Remission on Tumor Contamination 
Study by Dreyfus et al suggests that PBPCs from patients with 
relapsed refractory myeloma have a higher rate of tumor contamination. 
Tumor contamination was not found in one patient in remission, but was 
found in 31% of 16 patients in partial remission and 75% of four patients 
with refractory disease.90 
Jacquy C et al in their study found that complete clinical remission 
does not eliminate the potential for mobilizing tumor. As many as 50% of 
patients in complete remission from diffuse large cell lymphoma have 
mobilized tumor cells.91 
The Effect of Disease Stage and Mobilization on Tumor Contamination 
Ross et al, who found that patients with localized disease did not 
have tumor cells in PBPCs while patients with widespread metastatic disease 
had tumor contamination rates ranging from 17% to 100%.  
With the exception of bone, there was no correlation between the 
site of metastasis and the probability of finding tumor cells in PBPCs. On 
the other hand, marrow involvement was observed in six of the nine patients 
who had tumor cells in their PBPCs.92 
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Ladetto et al also found that all patients with advanced myeloma 
and marrow tumor also had tumor cells in PBPCs, suggesting that involved 
marrow is an important source of mobilized tumor cells. The authors 
concluded that both prevalence and concentration of tumor cells were low in 
blood before mobilization and that mobilization did not increase 
contamination. 93 
Thus, it remains controversial whether or in what circumstances 
mobilization of stem cells also mobilizes tumor cells. 
Effect of Mobilization Regimen on Tumor Contamination 
Different mobilization protocols have been studied for their effect 
on tumor contamination. Demirkazik et al found that patients who were 
mobilized with cytokines alone tended to have higher rates of tumor 
contamination in PBPCs than an unusual control group of nonmobilized 
patients. 94 
Knudsen LM et al in their study, cytokine mobilization was used for 
one collection while chemotherapy plus cytokines was used for the other, in 
random order. With each patient serving as his or her own control, tumor 
contamination was lower in PBPCs mobilized by chemotherapy plus 
cytokines than in PBPCs mobilized by cytokines alone.95 
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Mobilization kinetics of Tumor Cells can be Predictable 
In daily collections from myeloma patients, Gazitt and Tian E et al 
found that the collections richest in stem cells were obtained on days 1 to 3, 
whereas 75% of tumor cells were collected on days 5 and 6.96 
Gazitt Y et al in their study found that, only two of the 12 patients 
had >2.5% tumor cells on days 1 and 2, whereas 11 of 12 had >2.5% tumor 
cells by day 6. The same group also looked at low-grade (follicular) 
lymphoma to test the theory of differential mobilization of tumor. In this 
study, “poor mobilizers” (defined in part as those requiring ≥4 days of 
apheresis to yield 2 × 106 CD34+/kg) had lymphoma cells in 42% of PBPC 
collections as compared with 17% in “good mobilizers” who reached the 
same goal with 2 collections. 97 
Using TaqMan PCR and flow cytometry to detect tumor cells, 
Knudsen et al found that peak myeloma cell concentration in blood 
correlated with peak CD34+ cell concentration, regardless of mobilization 
regimen.95 
McCann JC et al found that, the differential mobilization of tumor 
cells apparent in some studies after administration of chemotherapy may be 
due to tumor cells mobilizing from two different sources with different 
kinetics.89 
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 Early mobilization may result from chemotherapy induced tumor 
necrosis, which causes haematogenous seeding as the primary tumor breaks 
down. Later mobilization may be due to release of metastatic tumor cells 
from marrow via the same mechanisms responsible for release of PBPCs.89 
Dreger P et al suggest that patients with marrow metastases or 
diseases intrinsic to marrow should undergo apheresis early after 
mobilization. This approach, however, would be limited by the extent of 
mobilization because many patients need to achieve a relatively high WBC 
count before adequate numbers of PBPCs can be collected.98 
In the subset of patients who mobilize well, a minimum number of 
LVL performed early in haematopoietic recovery may be preferable.  
PERIPHERAL BLOOD PROGENITOR CELL GRAFT 
MANIPULATION/GRAFT ENGINEERING AND ITS INFLUENCE 
ON ENGRAFTMENT 
The term “graft/cell engineering” is used to describe all varieties of 
stem cell graft manipulation, including removal of unwanted red cells or 
plasma from the stem cell graft to aid in stem cell cryopreservation or to 
reduce product volume before infusion for rapid engraftment. 
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Separation Methods99 
1.  Physical Methods 
Early physical separation methods were performed with routine 
laboratory equipment such as floor-mounted centrifuges to separate a 
mononuclear cell fraction containing the stem cells from the graft containing 
red cells. 
 Later improvements utilized more sophisticated blood bank 
equipment such as the COBE 2991 Cell Washer (Gambro BCT, Lakewood, 
CO) with sterile disposable plastic ware to separate and concentrate 
mononuclear cells.  
2.  Immunologic Methods 
The development of modern cell engineering techniques has been 
facilitated by improved phenotypic analysis with monoclonal antibodies and 
flow cytometry. The identification and characterization of the 115-kDa cell 
surface membrane molecule called CD34 on stem and committed progenitor 
cells allow specific haematopoietic progenitor cell isolation based on the 
presence or absence of CD34 and related antigenic markers.  
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The concept of positive or negative selection of cells based on cell 
surface phenotype identification upgrade the modern stem cell graft 
preparation. Coupling antibodies to magnetic beads, immunotoxins or 
microparticles offered new treatment options which significantly improve 
the outcome of stem cell transplantation.  
Flow cytometry based high-speed cell sorting is an alternative 
method for selecting haematopoietic progenitors and its subpopulations. 
a. Positive Selection  
Positive selection techniques are designed to separate the cells 
bearing an antigenic marker of interest in a graft. Such techniques can isolate 
highly purified cell subsets, and this can affect the outcome of stem cell 
transplants.  
The positive selection has been successfully employed to enrich 
stem or progenitor cell populations bearing the CD34 antigen this also 
accomplish some degree of separation of stem cells from contaminating 
precursors, mature immunocytes, and tumor cells. 
b. Negative Selection 
 Negative selection techniques are designed to remove the cells 
bearing an antigenic marker of interest from a stem cell graft. The negative 
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selection is similar to cytotoxic depletion but unlike cytotoxic depletion not 
only confined to a malignant population it includes interfering cells such as 
T cells or subsets. 
3. Tumour Cell Purging by Cytotoxic Depletion Techniques 
Early immunologic methods depend on incubating harvested 
marrow with tumour antibodies in the presence of complement to achieve 
selective tumour cell killing. Now cytotoxic drugs and tumour antibodies 
have been used to purge occult tumour cells from autologous stem cell 
grafts.  
Cytotoxic drugs such as mafosphamide or 4-
hydroperoxycyclophosphamide have been used to kill a broad range of 
tumour cells while sparing stem cells. Stem cells have high levels of 
aldehyde dehydrogenase, which degrade these pharmacologic agents and 
escape from these agents, but tumour cells lack aldehyde dehydrogenase 
enzyme. 
Application of Cell Engineering Techniques  
Much effort has been focused on methods to manipulate PBPC 
grafts to improve clinical outcomes due to shift in use from marrow to 
mobilised PBPCs. Both enrichment (Positive selection) and depletion 
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(Negative selection) techniques have been employed in PBPC engineering 
procedure. 
1. Tumor Purging and Engraftment 
The techniques that are designed to eliminate unwanted tumor cells 
from an autologous stem cell graft called “tumor purging”. The rationale for 
tumor purging comes from clinical studies indicating that “contaminating” 
tumor cells in such grafts may contribute to disease recurrence following 
transplantation. MA Diaz et al in their study found that tumour cell purging 
delays platelet engraftment100 
2.  Enrichment Methods for Stem/Progenitor Cells  
 The earliest prototypes for cell selection methodology were 
antibody-coated tissue culture flasks that bound CD34+ cells to their 
surfaces. Subsequently, a more user-friendly cell selection system was 
developed that used monoclonal anti-CD34 and avidin-biotin 
immunoabsorption chromatography to purify CD34+ haematopoietic 
progenitor cells.99 
The newer devices uses various platforms such as immuno 
magnetic or super paramagnetic iron dextran particles with monoclonal anti- 
CD34 conjugated for selection offers a closed system with sterile, disposable 
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plastic ware and clinical grade reagents and provides recovery of CD34+ 
cells with high purity.99 
In various trials conducted in patients with non-Hodgkin’s 
lymphoma, the selection procedure results in loss of about 50% of the 
CD34+ cells. 
3. T-Cell Depletion and Engraftment 
MA Dı´az1 et al reported that reduction in the number of T cells by 
manipulating allogeneic grafts before transplantation has been shown to 
reduce the incidence of graft versus host disease (GVHD).99 
Koh MB et al and Solomon SR et al found that positive selection 
for CD34+ cells can bring about up to a 5-log reduction in the T-cell content 
of a graft, 62-64 and the engraftment of CD34+ cells selected from allogeneic 
PBPCs is similar to unmanipulated PBPC grafts.101,102 
Mitsuyasu RT, Champlin RE, Gale RP et al and Noga SJ in their 
study found that T-cell-depleted grafts did not improve overall survival in 
patients compared with patients receiving unmanipulated stem cell grafts. 
Further ancillary cells in the stem cell graft that are mediators of GVHD are 
also important participants in stem cell engraftment and exhibit antileukemic 
activity.103,104  
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4. Cell Expansion and Engraftment 
Brugger W et al and Henschler R, et al stated that, at present, 
mobilized PBPCs are the preferred stem cell source for transplantation and 
point out that myeloid and lymphoid stem/progenitor cells can be expanded 
for up to 2 weeks in the presence of cytokines.105,106 
Boiron JM et al found that the empirical limit of engraftment speed 
with optimal CD34+ cell dose and growth factor administration is 
approximately 9 days. Preliminary clinical studies suggest that the time of 9 
days may be shortened in the future by co administration with HPCs that 
have been expanded, activated ex vivo, or both.107 
Tisdale JF et al and Haylock DN et al found that, adult CD34+ cells 
expanded ex vivo provide sufficient progeny to restore hematopoiesis in the 
short term, and expanded cells derived from PBPCs can correct neutropenia 
in transplant recipient’s promptly.108,109 
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HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)4 
The theoretical basis for stem cell transplantation came from the 
studies of Nowell and Ford, who demonstrated that bone marrow cells 
infused from one mouse in to a lethally irradiated mouse were capable of 
rescue by generating the entire repertoire of haematopoietic cells.  
Based on this the first unsuccessful allogenic transplants was 
performed by Sir Donnel E Thomas in 1957and then first successful 
syngeneic transplant in 1959in leukemia patients following total body 
irradiation. 
After understanding of the human histocompatibility, the first HLA 
matched sibling donor transplant was done by Dr Robert Good in an infant 
with immunodeficiency in 1968and by Sir Thomas in leukemia patient in 
1969.  
AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL 
TRANSPLANTATION 
Early Studies 
In the 1960s, animal studies detected stem cells in the circulation 
and, in the 1970s, haematopoietic stem and progenitor cells were identified 
in the human bloodstream. Subsequently transplantation of circulating 
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haematopoietic stem and progenitor cells was found to restore marrow 
function in lethally irradiated animals. 110 
However, to convert those observations in the clinical ground for 
therapeutic use, need development of techniques to collect the cells in large 
numbers. This was important because very few haematopoietic stem and 
progenitor cells circulate during steady-state haematopoiesis.111 
The problem was solved when a report appeared in 1974 showing 
that large numbers of human stem and progenitor cells could be collected 
with an apheresis instrument.103 Frequent apheresis procedures during steady 
state hematopoiesis and cryopreservation of the collected cells, allowed 
sufficient number of stem and progenitor cells for successful 
transplantation.112 
Clinical Trials 
McCarthy DM et al stated that, when the CML transformed to an 
accelerated phase, the patients received high-dose therapy and then their 
cryopreserved cells given to convert the disease to chronic phase. Forty 
seven of 50 patients recovered haematopoietic function with chronic phase 
disease but second chronic phase was short lived. 111 
 
58 
 
Goldman JM et al found that since the blood of these patients 
contains high number of haematopoietic stem and progenitor cells harvesting 
of these cells is possible with 2 to 4 apheresis procedures. 113 
The outcomes of these transplants were more encouraging and the 
following year descriptions emerged of six successful autologous transplants 
from six different institutions throughout the world.114 
ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL 
TRANSPLANTATION 
Allogeneic PBPC transplantation involves the transfer of cells from 
a normal donor to a recipient with either a malignant disease that was treated 
with high-dose therapy or an inherited marrow disorder that can be corrected 
by replacing the diseased marrow with normal cells. The patient and 
recipient must be matched closely for certain Histocompatibility antigens to 
avoid or minimize graft rejection and graft-versus-host disease (GVHD).190 
Clinical Trials 
The first clinical allogeneic PBPC transplant procedure was 
reported in 1989 and actually took place in late 1987, before cytokines were 
recognized as mobilizing agents. The clinical situation was unique because 
the matched sibling donor was unwilling to donate marrow but agreed to 
undergo multiple (10) apheresis procedures. 115 
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Dreger P et al stated that, while the result of the 1987 transplant 
could be considered a qualified success, no further allogeneic PBPC 
transplantation attempts were reported until 1993.116 Later that same year, a 
report of a successful allogeneic PBPC transplantation appeared.117 
Bensinger WI et al stated that, in early 1995, three reports, together 
describing successful transplantation of allogeneic PBPCs in 25 patients, 
appeared simultaneously and from that time, use of peripheral blood rather 
than marrow for allogeneic transplantation became more common. 118 
Anderlini P et al stated that, in 2001, the International Bone 
Marrow Transplant Registry and the European Blood and Marrow 
Transplant Group reported that 1488 allogeneic PBPC transplants were 
reported between 1994 and 1998 by 152 teams, while in 1998, 26% of 
allogeneic transplants used PBPCs.119 
Bensinger WI et al in their study found that randomized prospective 
studies have shown that haematopoietic recovery following transplantation 
of allogeneic PBPCs is more rapid than that of marrow.120 
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CHANGING SCENARIO  
Present Scenario in the World 4 
Currently 55,000 to 60,000 Haematopoietic Stem Cell Transplants 
are performed worldwide. In 1970s, non-malignant diseases, like aplastic 
anemia (40%) and immune deficiencies (15%) were the major indications 
for HSCT. From 1985 to till date haematological malignancies (leukemia’s 
70%) are main indication for HSCT.  
Aplastic anemia and immune deficiencies now account for 5% of 
allogenic transplants. Multiple myeloma is the most common (48%) 
indication for autologous transplants. Non-Hodgkin lymphoma (28%) and 
Hodgkin lymphoma (12%) is next common. Solid cancers account for 10% 
of all autologous stem cell transplants. 
 There are currently more than 1.5 million HLA-A,B and DR 
matched marrow donors registered in bone marrow donor registries 
worldwide,50% of the patients who require haematopoietic stem cell 
transplantation are still unable to find a suitable matched donor  
Present Scenario in our Country 
The data from six transplant centers in India were collected and it 
was found that a total of 1540 allogenic and autologous bone marrow 
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transplantations (BMT) have been performed in a country of over one billion 
population. Presently, more than 40,000 stem cell transplantations are being 
performed annually worldwide. In India, the transplantation procedure is 
being practiced in the larger transplant centers, located mostly in western, 
northern and southern India. 121 
 In India, Haematopoietic Stem Cell Transplant Centre’s are 
 AIIMS, New Delhi  Apollo Hospital, Hyderabad  
 Christian Medical College, Vellore  Rajiv Gandhi Cancer Institute New Delhi 
 Cancer Institute (WIA), Chennai  Command Hospital (SC), Pune 
 Tata Memorial Hospital, Mumbai   Cancer Care Trust Hospital, Indore  
 Apollo Cancer Hospital, Chennai   PGIMER,Chandigarh. 
 SGPGI, Luknow  Apollo Hospital, Hyderabad  
 Army Hospital R&R New Delhi  
 
 
Types of Haematopoietic Stem Cell Transplantation (HSCT) 
Before the administration of the HPC product, the recipient is 
“conditioned.” In patients with neoplastic diseases in both the allogeneic and 
autologous settings, the purpose of the conditioning regimen is to reduce the 
tumor burden. In the allogeneic setting, the conditioning regimen also 
creates “space” for the transplanted cells via myeloablation and suppresses 
the patient’s immune system to allow for engraftment of the donor cells.122 
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 Recently, conditioning regimens have been classified as123 
1) Myeloablative, 
2) Reduced intensity,  
3) Nonmyeloablative.  
 
Haematopoietic stem/progenitor cell transplants fall into one of three 
categories4 
1. Autologous (Self)  
2. Allogeneic (HLA-matched related or unrelated) 
3. Syngeneic (Identical sibling) 
Autologous  
Intravenous infusion of patient own haematopoietic stem cells to 
rescue patient bone marrow due to severe bone marrow injury caused by 
high dose chemotherapy or radiotherapy as a part of treatment for the 
disease.  
Allogenic 
Infusion of haematopoietic stem cells from related or unrelated 
donor depending on the donor further classified as follows. 
HLA Matched Related Sibling  
Intravenous infusion of haematopoietic stem cells obtained from 
siblings. Every individual has a 33% chance of having a matched sibling 
donor. 
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HLA Matched Unrelated Donor 
With the availability of bone marrow donor registries worldwide, it 
is now possible to find HLA Matched unrelated donors from these registries. 
It takes approximately 3 to 6 months with the availability of high resolution 
HLA match and better supportive care HLA Matched unrelated donors 
transplants now account for about half of all allogenic transplants 
worldwide. 
Syngeneic 
The transplant obtained from syngeneic twins which have the 
advantage of least complication due to complete HLA match. 
Haploidentical Transplants 
Donors share one haplotype with the recipient and mismatched for 
one or more antigens on the unshared haplotype with partial success. 
However this technique requires T-cell depleted grafts to reduce the 
possibility of life threatening GVHD. 
Indications for Haematopoietic Transplantation116 
Malignant diseases are the most common indication. Newer 
transplant trends include use in inborn disorders of metabolism, sickle cell 
disease, beta thalassemia major and autoimmune disorders. The success rate 
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of HPC transplantation depends on the disease of the patient being treated; 
the stage of the disease; the degree of prior treatment; the age and condition 
of the patient; and, in the case of allogeneic transplantation, the degree of 
HLA match between the donor and the patient. 
Indications for Haematopoietic Stem Cell Transplantation 
 
   
 
 
 
 
 
 
 
Malignant or Clonal Disease of the 
Marrow 
Acute leukemia 
Chronic myelogenous leukemia 
Hodgkin & nonHodgkin lymphoma 
Myelodysplatic syndromes 
Myeloproliferative disorders 
Multiple myeloma 
Chronic lymphocytic leukemia 
Solid Tumours 
Breast cancer 
Ovarian cancer 
Renal cell carcinoma 
Testicular cancer 
Hemoglobinopathies 
Thalassemia 
Sickle cell disease 
Childhood Solid Tumours 
Wilm tumor 
Neuroblastoma 
Rhabdomyosarcoma 
Ewing sarcoma 
High-grade gliomas 
Congenital Immune Deficiencies 
SCID 
Wiskott Aldrich syndrome 
Marrow failure syndromes 
Severe aplastic anemia 
Fanconi anemia 
Congenital hypoplastic anemia 
Inborn Errors of Metabolism 
Mucopolysaccharidoses 
Leukodystrophies 
Glycoprotein disorders 
Lysosomal storage disorders 
Osteopetrosis 
Osteogenesis imperfect 
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PBSC ENGRAFTMENT 
The speed of engraftment is measured by the number of days after 
infusion of the graftuntil a defined threshold of circulating neutrophil s 
(polymorphonuclear cells, or PMNs) or platelets is reached, typically the 
first of 3 days for PMNs >500/μL and platelets >20,000/μL, without 
transfusion.188,124 
 
FACTORS REPORTED TO AFFECT THE RATE OF NEUTROPHIL 
ANDPLATELET ENGRAFTMENT 
Infused dose of viable CD34+ cells/kg 
Use of posttransplant growth factor 
Type of pretransplant preparative regimen  
Ease of mobilizing the donor 
Extent and type of prior chemotherapy or radiotherapy 
Patient or donor age 
 
Graft Source and Engraftment 
However, according to the results of large scale retrospective 
comparisons of unrelated donor marrow transplantation using HPC(A), 
HPC(M), or HPC(C), the potential advantages of HPC(A) or HPC(M) include 
more rapid engraftment, fewer graft failures, and an ability to obtain 
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additional cells if they are needed because of poor recipient engraftment or 
disease relapse.125 
Visani G et al in their study found that, as a result of the 
administration of higher progenitor cell doses, autologous transplantation 
using HPC (A) grafts is associated with shorter times to neutrophil  and 
platelet engraftment than HPC (M) grafts with fewer transfusions, fewer 
infections, shorter hospital stays and, in some studies, lower overall costs.126 
Talmadge JE et al in their study found that immunologic recovery is 
also more rapid using HPC (A) when compared with HPC (M).127 
Bensinger WI et al and  Ringden O et al stated that related allogeneic 
donor transplantation in adults who received myeloablative conditioning also 
show that HPC (A) grafts are associated with shortened time to neutrophil  
and platelet engraftment with fewer transfusions, fewer infections, and shorter 
hospital stays when compared with HPC (M).128,129 
Storek J et al concluded that recovery of immune cells and function 
are both more rapid after HPC (A) transplantation compared with HPC (M), 
both after related and matched unrelated allogeneic transplantation.130 
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Dey BR et al conducted a randomized clinical trial in adults to 
determine the advantages and disadvantages of both sources of HPC grafts 
for allogeneic transplantation in different diseases. Initial reports suggest 
that the advantages of rapid engraftment speed and disadvantages of chronic 
GVHD appear to apply as well to unrelated donor or nonmyeloablative 
conditioning using HPC (A) versus HPC (M) grafts according to 
observational studies.131 
Following an evidence based review by executive committee, 
American Society for Blood and Marrow Transplantation, an expert panel 
recommended the preferential use of HPC (M) for matched related donor 
transplantation in paediatric patients who have AML and are in first 
remission, but no recommendation was made for unrelated- donor marrow 
transplantation.132 
Richard K.Shaddu et al in their study found that in the autologous 
setting patients receiving apheresis derived PBSC transplants typically have 
faster neutrophil  and platelet recoveries than bone marrow derived transplant 
and need fewer red cell and platelet transfusions. 133 
William I. Bensinger et al in their study reported that patients had 
rapid engraftment of both granulocytes and platelets after allogenic PBPC 
transplant and platelet engraftment was more rapid than bone marrow derived 
transplant.134 
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Martin Korbling et al in their study concluded that the use of 
PBPCs for transplantation represents a major advance. The temporary 
peripheralization of haematopoietic progenitor cells allows collection of 
large doses of progenitors and has a significant advantage for the donor 
including avoiding the need for general anesthesia and multiple BM 
aspiration. 135 
PBPC transplantation provides rapid hematologic recovery and in 
most studies has reduced hospitalization and costs. PBPCs are as effective as 
BM for autologous transplantation for the same indications as autologous BM 
transplantation has been proven efficacious. Allogeneic PBPC transplants are 
promising and do not appear to increase the risk of acute GVHD in 
preliminary studies.135 
CD34+ Cell Dose and Engraftment 
Attilio Oliveri et al in their study found that CD 34 cell dose is the 
only significant factor that affects neutrophil and platelet engraftment in 
haematological malignant patients who received G-CSF mobilised autologous 
pbsc after high dose chemotherapy. 
 In their study they concluded that optimal dose for rapid and 
complete engraftment ranges between 5 and 7.8×106 /kg CD34+ cell dose 
and a graft size ranging from 2.5 to 4.9×106 /kg CD34+ cell dose is safe for 
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complete stable and rapid neutrophil engraftment but not for rapid platelet 
engraftment and <2.5×106 /kg CD34+ cell dose is still optimal for neutrophil 
engraftment but not platelet engraftment and >7.8×106 /kg CD34+ cell dose 
is not advantageous.136 
 J.A.Perz-Simon et al  in their study found that the time to 
engraftment significantly influenced by the number of CD34+ cell dose 
infused and they concluded that dose of 0.75×106 CD34+ cells per kg is 
sufficient for engraftment in all patients receiving autologous PBPC 
transplant.69 
Similarly Bensinger et al also in their study found that the CD 34 
cell dose is the only significant factor that affects neutrophil and platelet 
engraftment.137,138 
Similarly H.E.Johnsen et al in their study found that the CD 34 cell 
dose is the only significant factor that affects time to neutrophil  and platelet 
engraftment and they concluded that the quality assessment of autografts 
have fulfilled by enumerating CD34+ cell subset with flow cytometry.139 
Similarly J.Reiffer et al also in their study found that the dose 
infused is the only significant factor that affects neutrophil and platelet 
engraftment.140 
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Similarly S Heimfeld et al also in their study found that the dose of 
CD34+ cells infused is the only significant factor that affects neutrophil and 
platelet engraftment.141 
Bensinger W et al in their study found that CD34+ cell content was 
considered predictive of engraftment kinetics for neutrophil s and platelets. 
The minimum number of CD34+ cells required for rapid engraftment is also 
depend on the clinical setting, it may be twofold higher for heavily pre-
treated patients.87 
Civin CI, Strauss LC, Brovall C, et al found that in allogeneic 
transplantation, complete and sustained engraftment of neutrophil  and 
platelets has been occurred after 2.2to2.5 × 106/kg CD34+ cell dose 
infusion.142 
Rusten LS, Lyman SD, Veiby OP et al found that in case of 
autologous PBPC transplantation neutrophil and platelet engraftment 
occurred for all patients with advanced-stage or poor-prognosis malignant 
lymphoma who received >2.5 × 106 CD34+ cells/kg in patients and 
neutrophil engraftment took >2 weeks and platelet counts of 20,000/μL were 
not achieved until a median of 31 days in patients receiving fewer <2.5 × 106 
CD34+ cells.143 
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Berenson RJ, Andrews RG, Bensinger WI, et al found that the 
influence of the CD34+ cell dose was so strong that the collection protocol 
was changed to specify a CD34+ cell dose of 5 × 106/kg rather than 5 × 108 
MNC/kg.144 
Bender JG et al and Tricot G et al stated that higher administered 
doses of CD34+ cells increase the speed of engraftment for both neutrophils 
and platelets, especially in heavily pretreated patients.129, 130 Administration 
of >5 × 106 viable CD34+ cells/kg is generally not advantageous, and 
administration of <2×106 CD34+ cells/kg may compromise both the 
probability and speed of engraftment. 145-147 
Autologous PBSC Transplantation  
Richman CM stated that significant increase in circulating 
progenitors 2 to 3 weeks after administration of myelosuppressive 
chemotherapy was reported in 1976.148 
Juttner CA et al stated that these chemotherapy mobilized cells 
were collected, cryopreserved and reinfused following high-dose therapy. 
Hematopoiesis was restored in the patients, demonstrating that 
chemotherapy-mobilized stem and progenitor cells could provide a 
successful autograftproduct.149 
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Beyer J et al stated that from 1986 to 1991, autologous PBPC graft 
products were collected either in the steady state or after chemotherapy 
induced mobilization. Since chemotherapy induced mobilization increased 
the number of stem and progenitor cells in the blood, fewer apheresis 
procedures were required to collect a satisfactory graft product. In addition 
mobilized cells provide faster haematopoietic engraftment 
followingtransplantation.150 
Allogeneic PBSC Transplantation  
J.Szer et al in their study found that allogenic PBPC from HLA 
identical siblings speed the engraftment of neutrophil s and platelets without 
detrimental effects on GVHD or survival.151 
Lee SH and Heimfeld.S et al stated that in allogeneic 
transplantation, CD34+ cell dose was also associated with decreased 
transplant-related mortality and relapse, as well as with improved overall 
patient survival.152,153 
Pulsipher.MA et al and Heimfeld.S et al stated that however, 
because of the generally longer time to neutrophil engraftment and 
especially to platelet engraftment associated with allogeneic transplantation 
and with unrelated donors in comparison with autologous patients, a higher 
HPC(A) dose (at least 4 × 106 CD34+ cells/kg) is preferred.152,154 
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Administration of higher doses of CD34+ cells from related or 
unrelated, fully or partially matched donors that are given to adults or 
children is consistently associated with more rapid neutrophil and platelet 
engraftment. 155 
 Heimfeld S et al and Zaucha JM et al stated that however, survival 
benefits are controversial because studies of adult or pediatric patients who 
received allogeneic HPC (A) transplants from sibling donors for ablative 
therapy show that very high CD34+ doses (>8× 106/kg) were associated with 
increased morbidity resulting from chronic GVHD, a common cause of 
severe morbidity and mortality after allogeneic transplantation and with no 
improvement in survival.154, 156 
Pulsipher MA et al and Perez-Simon JA et al stated that however, 
graft selection and CD34+ cell dose should be individualized, because 
reports also indicate that increased CD34+ cell doses are associated with 
more rapid full-donor chimerism and may improve survival in high-risk 
leukemia patients who undergo nonmyeloablative regimens using HPC (A) 
from HLA-identical sibling donors or in standard to high risk patients after 
ablative or nonablative marrow transplantation using matched unrelated 
donors.152,157 
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Autologous Vs. Allogeneic 
Thissiane et al in their study found that faster neutrophil and 
platelet engraftment was achieved in autologous PBSCT than allogeneic 
PBSCT.158 
Disease Type  
Thissaiane et al in their study on autologous and allogeneic PBSCT 
in 65 patients with hematological malignancies revealed multiple myeloma 
patients achieve rapid neutrophil and platelet engraftment than lymphoma 
and leukemia.158 
M. J. Watts et al in their study on 20 patients who underwent 
autologous PBSCT found that multiple myeloma patients had earlier platelet 
engraftment than lymphoma patients.159 
J. Reiffers et al in their study on 118 patients with hematological 
malignancies found AML patients achieved delayed engraftment than other 
malignancy.161 
 Shirong Wang et al in their study found that in each diagnostic 
subgroup, a stronger correlation between CD34+ cell dose and engraftment 
was seen in patients with MM and NHL. Patient sex was not a confounding 
factor in whole population analysis, except there were minor differences in 
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some diagnostic groups in the relationship between CD34+ cell dose and 
engraftment speed; that is, female AML patients engrafted much faster when 
they received a higher dose of CD34+ cells, while this was true for male 
patients with NHL. Patient age at transplantation did not confound the 
results. 162 
Conditioning Regimen 
 J.Reiffers et al in their study found that busalphan and total body 
irradiation conditioning regimens slower the engraftment.160 
 Mauricette Michellet et al in their study on pretransplantation and 
posttransplantaion factors and their impact on outcome found that the 
conditioning regimen had significant influence on engraftment. 
 Peter Dreger et al in their study on autologous progenitor cell 
transplantation found that BCNU and melphalan conditioning regimens had 
adversely affect PBCS graft performance engraftment164 
 Charles H. Weaver et al in their study on autologous HSCT found 
that patients receiving high dose cyclophosphamide, thiotepa and carboplatin 
regimens had more rapid platelet engraftment than patients receiving other 
regimens. Patients requiring two mobilization procedures to achieve ≥    
2.5×106 CD 34 + cells /kg experienced slower platelet engraftment.191 
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Bensinger WI et al and Dreger P et al stated that apart from CD34+ 
dose, additional factors that have been reported to affect engraftment after 
autologous transplantation include the type and extent of previous 
myelotoxic therapy (engraftment is slower after total body irradiation (TBI) 
or busulfan) and whether the patient was a poor HPC mobiliser 166,167 
Thissiane et al in their study, found that CBV, melphalan (M200) 
and Flu Cy conditioning regimens show faster engraftment than others and 
Cy TBI and Bu Cy achieve delayed engraftment than others.158  
HLA Match 
J. Szer et al in their study found that allogeneic PBPC from HLA-
identical siblings speed the engraftment of neutrophil s and platelets without 
detrimental effects on GVHD or survival.151 
Pulsipher M A et al in their study found that administration of 
higher doses of CD34+ cells from related or unrelated, fully or partially 
matched donors that are given to adults or children is consistently associated 
with more rapid neutrophil and platelet engraftment. 155,168 
Schulenburg A et al and Storek J et al stated that Immunologic 
recovery may be prolonged for up to a year, especially when the donor is 
unrelated, and prolonged immunologic recovery is associated with increased 
infections.130,169 
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Blood Group Match 
G Stussi et al. in their study on 562 patients with allogeneic 
haematopoietic stem cell transplantation found that ABO incompatibility has 
no influence on neutrophil  and platelet engraftment and that only RBC 
engraftment was delayed (particularly in major ABO incompatibility)they 
also suggest that ABO incompatibility does not seem to affect the outcome 
in most patients of stem cell transplant.170 
Previous Radiotherapy and Chemotherapy   
 Peter Dreger et al in their study on autologous progenitor cell 
transplantation found that previous chemotherapy and radiotherapy had no 
influence on engraftment.164 
Ross AA et al in their study found that the extent of prior 
chemotherapy may also have an effect on engraftment kinetics. This was 
seen in a large trial of double stem cell transplantation for multiple 
myeloma. In addition, even 6 months of treatment with alkylating agents like 
methotrexate, significantly delayed engraftment in extensively pretreated 
patients, the CD34+ cell yield required for rapid platelet engraftment 
increased from 2 × 106/kg to 5.0 × 106/kg.171 
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Age and Engraftment 
Similarly Thissiane et al revealed that PBSC engraftment was more 
rapid in the 50-59 year age group and they found this finding could be due to 
the fact that associated favorable factors like autologous source of PBSC and 
received melphalan 200 and CBV conditioning regimen which were also 
associated with faster engraftment.158 
 Shaji K. Kumar et al in their study found that the proportion of 
patients attaining WBC engraftment (as indicated by an ANC >500 for three 
consecutive days) by day 15 was 94% for the elderly group (≥70years) 
compared to 78% for the control group(≤65)  Similarly, the proportion of 
patients achieving a non-transfused platelet count of over 50,000 by day 30 
was similar for both groups (81% and 80% respectively) and they concluded 
that chronologic age alone should not be used to decide on transplant 
eligibility.172 
 DMSO Depletion  
Cigdem A. Akkok et al in their study concluded that simple single 
wash DMSO depletion causes significant CD34+ cell loss and delayed 
platelet engraftment and increased platelet transfusion requirement. They 
suggest this procedure should be recommended for those patients with 
increased risk of toxicity.173 
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Sex 
Thissiane et al their study found that male gender achieved faster 
neutrophil and platelet engraftment than female gender.158 
Number of Mobilization  
 Fraipont.V in their study found that autologous PBPC obtained 
from 2nd mobilisation with chemotherapy plus G-CSF after first failed 
mobilisation with chemotherapy plus G-CSF delays engraftment.174 
Second Apheresis Yield (Graft) from Poor Mobilisers and Engraftment 
M. J. Watts, al. in their study on previously treated patient’s 
conclude that poor mobilizers on second attempt yield adequate cells to 
enable high dose therapy and prompt engraftment and remobilisation is 
worth among these patients.159 
Large Volume Leukapheresis vs. Normal Volume Leukapheresis 
J.F.Abrahamsen et al. in their study showed that LVL leukapheresis 
yields more CD34+ cells particularly in poor mobilizers and faster 
engraftment of platelets (10 days for LVL and 11 days for NVL) and 
neutrophil engraftment is 10 days for both LVL and NVL. 175 
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 Pettengal et al in their study showed that long term engraftment 
achieved from single LVL apheresis in an attempt to reduce number of 
apheresis procedure.176 
Collection and Engraftment 
Schwella et a1 in their study reported that when the number of 
circulating CD34+ cells is greater than 40 per µl, more than 2.5 x 106 
CD34+ cells per kg can be collected, resulting in a rapid 
haematopoieticengraftment.200,69 
Good and Poor Mobilisers and Engraftment 
 Liuyan Jiang et al in their study concluded that haematopoietic 
stem cell source from good and poor mobilisers show similar time to 
engraftment particularly neutrophil engraftment which is a most sensitive 
predictor for long term engraftment.177 
Similarly Shirong Wang et al in their study concluded that poor 
mobilizers can still benefit from autologous haematopoietic stem cell 
transplantation and the efficacy of haematopoietic stem cell mobilization and 
collection, defined as number of days to reach a CD34+ cell dose of 2 × 106 
per kg, and should not be used independently to estimate posttransplantaion 
engraftment.162 
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Density-Enriched Peripheral Blood CD34+ Cells  
 Thai M.Cao et al. in their study found that allogeneic 
transplantation with density enriched PBPC CD34+ graft resulted in rapid 
haematopoietic engraftment with no incidence of graft failure in patients 
with advanced haematological malignancy.  
Neutrophil engraftment was rapid with median time to ANC greater 
than 0.5 × 109/L taking place at 10.5 days (range, 8–18 days). The median 
time to a platelet count greater than 20× 109/L was 13 days. 178 
Positively CD34+ Cell Selection   
 Wichard Vogel et al in their study concluded that in both allogenic 
and autologous PBPC transplantation setting the time to engraftment is not 
different between positively selected CD34+ cells and unmanipulated 
CD34+ cells.179 
Ex Vivo Expansion  
 Wichard Vogel et al in their study found that ex-vivo expansion 
shorter the PBSC engraftment time. 179 
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T cell Depletion 
William I. Bensinger et al in their study reported that the addition of 
T cell-depleted PBSC assisted the establishment of allogeneic 
engraftment.168 
G-CSF Dose  
Marc Andrew et al in their study concluded that the engraftment 
data of 5 and 10 µg per kg filgrastim mobilised groups (group A 5  µg per 
kg, group B 10 µg per kg) produce similar engraftment time( 8 days for 
neutrophil engraftment and 9 days for platelet engraftment for both group A 
and B ).180 
Plerixafor 
Nina Worel et al, in their study concluded that plerixafor in 
combination with G-CSF is an effective and well-tolerated mobilization 
regimen in patients with previous mobilization failure. Importantly, patients 
mobilized with plerixafor presenting with low PB CD34+ cell counts on the 
first day of apheresis show more efficient stem cell collections than patients 
mobilized without plerixafor. The median dose of PBSC graft infused was 
2.93 × 106 CD34+ cells/kg recipient body weight. The median numbers of 
days to neutrophil and platelet engraftment were 12 and 15day, 
respectively.181 
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Freezing and Storage Procedure  
Virginia Fisher et al in their study found that G-CSF mobilised 
PBSC that have been collected from unrelated donors can be stored, 
transported and cryopreserved without a significant loss of CD34+ cells. 
Nevertheless in marked difference, under the same conditions, there is a 
significant reduction in viable CD34+ cells cause delayed PBSC 
engraftment.182,183 
Pegfilgrastim (G-CSF) Vs. Filgrastim (G-CSF) 
Simone Cesaro et al in their study found that a single dose of 100 
mg/kg pegfilgrastim can be used successfully for PBSC collection, and the 
resulting autografts have an overall morbidity and rate of neutrophil and 
platelet engraftment similar to that observed in autografts performed with 
filgrastim-stimulated PBSC.184 
Preceding Chemotherapy, Tumour Load and Age Influence 
Engraftment in Multiple Myeloma Patients Mobilized With 
Granulocyte Colony-Stimulating Factor Alone. 
 K. R. Desikan et al in their study on multiple myeloma patients 
concluded that disease status, previous therapy with alkylating agents had 
minimal effect on engraftment and tumour load had significant impact on 
engraftment (delay the speed of engraftment). They also found the number 
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of CD34+ cells/kg infused remains an important determinant of rapidity of 
engraftment irrespective of mobilization regimens used.185 
Cell Viability and Engraftment 
 S. Lee et al in their study concluded that quantification of post-thaw 
viable CD34+ cells better represents the actual composition of the graft and 
may be a more accurate predictor of haematopoietic engraftment than post-
thaw total CD34+ cell counts, or prefreeze determinations, especially for 
platelet engraftment. It is necessary to develop good quality controls for 
freezing and thawing procedures to minimize variance in cell viability.186 
Post Transplant G-CSF and GVHD Prophylaxis Use. 
 A Urbano-Ispizua et al in their study on 33 patients with allogenic 
PBSCT found that the speed of neutrophil engraftment strongly influenced 
by the use of rhG-CSF post transplant and marginally by the type of GVHD 
prophylaxis which contain MTX (Methotrexate). 187 
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MATERIALS AND METHODS 
The study was conducted in the Department of Transfusion 
Medicine, The Tamilnadu Dr.M.G.R. Medical University Guindy, in 
collaboration with the Cancer Institute Adyar (W.I.A), Chennai. 
In our study between June 2013 and August 2014, the factors 
influencing the engraftment of haematopoietic stem cell transplantation for 
patients with haematological malignancies were analyzed based on the 
neutrophil and platelet engraftment criteria. 
As per AABB188, the speed of engraftment is measured by the 
number of days after infusion of the graft until a defined threshold of 
circulating neutrophils (polymorphonuclear cells or PMNs) or platelets is 
reached, typically the first of three days for PMNs >500/µL and platelets 
>20,000/µL, without transfusion.  
Accordingly, the following factors were analyzed: 
1. Patient Related Factors 
 Patient Age Group 
 Patient Sex  
 Diagnosis 
2. Donor Related Factors 
 HLA match   
 PBSCT Type (Autologous/Allogeneic)  
 ABO Blood Group Match  
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3. Treatment Related Factors 
 Previous Chemotherapy  
 Previous Radiotherapy   
 Conditioning Regimen (Reduced intensity/Myeloablative)  
 
4. Graft Related  
• CD 34+ cell Dose Infused (Per kg recipient body weight) 
• CD34+ cell Viability  
The following inclusion and exclusion criteria were applied 
Inclusion criteria 
All patients with haematological malignancy undergoing 
haematopoietic stem cell transplantation with written consent. 
Exclusion Criteria 
Patients undergoing haematopoietic stem cell transplantation for 
disorders other than   haematological malignancy. 
Details of PBSCT Procedure Followed in Our Study Centre  
1. Mobilization  
2. Collection and Cryopreservation 
3. Enumeration of Haematopoietic Stem Cells  
4. Pretransplant match for allogenic PBSCT 
5. Patient preparation and PBSCT 
6. Post Transplant Care 
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1. Mobilization 
i) Autologous Donor 
ii) Allogenic Donor 
 
Autologous Donor 
 
After completing chemotherapy and referral from the treating 
physician along with informed consent, autologous donors (patients) were 
mobilised with either G-CSF alone or G-CSF with plerixafor (CXCR4 
competitive inhibitor). 
 For donors with G-CSF alone, 10µg/kg body weight/day 
subcutaneous injection of G-CSF for four days was given and stem cell 
collections by apheresis were started on fifth day. 
For donors with G-CSF with plerixafor, G-CSF 10µg/kg body 
weight was given for four days, followed by a single dose of plerixafor 
0.24mg/kg body weight subcutaneously, stem cell collection by apheresis 
were started after approximately 11 hours of plerixafor injection.10 
Allogeneic Donor 
After obtaining fitness opinion from the physician along with 
informed consent from the allogeneic donors, the same mobilization regimen 
used for autologous donors were followed. 
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2. Collection and Cryopreservation 
Apheresis were carried out using an automatic blood cell separator 
Haemonetics MCS +LN 9000-220 E intermittent type stem cell collection 
device, after establishing  peripheral vein/central vein access line under 
aseptic precaution, with 80 mL/min draw speed, 50ml/min recirculation 
speed, 30ml/min collect speed with ACD anticoagulant in the ratio 1:9 to 
1:12. 
The final product collected in the stem cell bag were either stored at 
40C for immediate use within 48 hours or for long term storage they were 
cryopreserved in DMSO (7.5 % Final concentration) with a controlled-rate 
freezing device and stored at -700C in the mechanical freezer. 
3. Enumeration of HSC  by ISHAG protocol189 
Under aseptic precaution 3ml of stem cell product from the stem 
cell bags were collected in to the sterile disposable 5 ml syringe with the 
help of sterile connecting device and aliquoted in to 1ml each in to three test 
tubes after proper labeling, for the following tests to measure the graft size 
by using flowcytometry: 
i. Total Nucleated Cell count  
ii. Absolute Mono Nuclear Cell count/CD 34+ cell count 
iii. CD34+ cell viability 
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The harvest size was calculated after each leukapheresis by total 
nucleated cell count, MNC count, CD34+ cell viability and cytofluorimetric 
count of CD34+ cells. MNC were identified by basophil channel H*1-
Technicon coulter. The CD34+ cells were counted using a Becton-Dickinson 
FACScan after erythrocyte lysis (EDTA-ammonium- chloride solution) and 
direct incubation for 30 minutes with phycoerythrin (PhE) conjugated 
monoclonal anti-CD34+ antibody. 
 CD34+ cell counts were performed both in open gate, considering 
the whole cell population, and by choosing a proper lymphomonocyte 
population as follows: the entire population was gated using double staining 
with anti-CD45/14 PhEFITC conjugated antibodies; in this way only those 
cells with lymphomonocyte scatter characteristics were acquired, and the 
double staining with anti- CD34/14 PhE-FITC conjugated antibodies ruled 
out non-specific binding by the monocytes. (Fig.2) 
 A negative control for non specific fluorescence as used with 
unstained cells; the minimal number of events acquired for each 
determination was 20,000 and the entire procedure was performed at 4 °C. 
In all cases only the CD34+ cell count performed in the lymphomonocyte 
gate has been considered for data analysis.  
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(Fig.2) Viable CD34+ cell event in flowcytometry 
  
Absolute CD34+ cell count which is expressed by number of cells 
per microliter is converted in to CD 34+ cell dose by following formula, 
 
                   CD 34+ cells/µL × Volume of the stem cell (ml)   
CD 34+ cell dose   =           ---------------------------------------------- 
                                 Recipient body weight (Kg) 
 
 
4. Pretransplant match for allogenic PBSCT 
In allogenic PBSCT setting donor and patient were evaluated for 
viral status (CMV IgG, CMV IgM, HSV IgG, HSV IgM, Hepatitis BsAg, 
Hepatitis BcAb, HCV, HIV, and VDRL.  Patient and donor HLA match 
done by either high resolution HLA matching (10/10) or low resolution HLA 
matching (6/6), ABO blood group by serology.      
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5. Patient Preparation and Peripheral Blood Stem Cell Transplantation  
Prophylactic drug regimens were started on day -7, depending on 
the diagnosis, all patients myeloablated by giving appropriate conditioning 
regimens started on day -3, after completion of conditioning regimen, PBSC 
were infused on day 0 with steroid cover. 
Conditioning  regimens  included, fractioned total body irradiation 
(TBI 1200 cGy) with cyclophosphamide 60mg/kg, melphalan 200mg/m2, 
busalphan 1mg/kg with cyclophosphamide 60mg/kg in, lomustine 
200mg/m2, ARA-C 2000mg/m2 cyclophosphamide1800mg/m2, 
etoposide1000mg/m2 (LACE) in 6, Cyclophosphamide 750mg/ m2  and 
carmustin 112.5mg/ m2 (BCNU)  with etoposide200mg/ m2 (VP-16) in 1 
patient. 
6. Post Transplant Care 
 During the aplastic phase all patients were kept in a positive 
pressure HEPA filtered room and received antimicrobial prophylaxis with 
ciprofloxacin 1000mg/day and fluconazole 100 mg/day orally and 
acycloguanosine15 mg/kg/day intravenously. 
All patients received G-CSF 5 μg/kg/day until WBCcount reached 
0.5×109/µL starting after Peripheral Blood Stem Cell Transplantation, 
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irradiated blood products were given in order to maintain the hemoglobin 
and platelet levels over 8 g/dL and 20,000×109/µL, respectively. 
The values (speed of engraftment) obtained for individual factors 
will be analyzed based on median and range. 
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RESULTS 
A total of 36 patients undergoing PBSCT procedure were 
prospectively observed during the study period. Out of 36 patients 5 patients 
was not received peripheral blood stem cell transplantation due to inadequate 
yield of peripheral blood stem cells by apheresis, in the remaining 31 
patient’s one patient died before engraftment. 
 In the present study on factors influencing peripheral blood stem 
cell transplantation in 30 patients with hematological malignancies, the 
speed of engraftment was assessed by the first appearance and persistence of 
neutrophils of >500cells/µL and platelets of >20,000/µL respectively, 
without transfusion for three consecutive days. 
The speed of PBSC engraftment based on neutrophil and Platelet 
appearance in 30 patients of hematological malignancies was analyzed based 
on the median values obtained for each of the factors studied.  
 In our study, the range observed was between 4 and 21 days for 
neutrophil engraftment. The range observed for platelet engraftment was 
between 10 and 46. In the remaining 1 case, which was diagnosed as CLL, 
the patient died due to multi-organ failure on the 11th day post PBSC 
infusion, neutrophils did not appear till then. 
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The data obtained for various factors analyzed for the speed of PBSC 
engraftment are as follows: 
1. DISEASE 
Frequency Distribution of Disease 
Table.1       
 
Disease and PBSC Engraftment 
Table.2 
Diagnosis Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Multiple Myeloma 10 
 (4-12)* 
13 
(11-19) 
Lymphoma 
(HL,NHL) 
11 
(13-46) 
16.5 
(13-46) 
Leukemia 
(ALL,AML,CML) 
14 
(12-21) 
25 
(10-30) 
*Range 
 
 In our study among hematological malignancies, MM, lymphoma and 
leukemia patients achieve neutrophil engraftment in median on day10, 11 and 
14 respectively  
  Platelet engraftment occurred in median on day13, 16.5 and 25 respectively. 
(Table.1,2) 
11
8
11
0
2
4
6
8
10
12
MM Lymphoma Leukemia
DISEASEDiagnosis Frequency Percent 
MM 11 36.7 
Lymphoma 8 26.7 
Leukemia 11 36.7 
Total 30 100.0 
95 
 
2. CD 34+CELL DOSE  
 
Frequency Distribution of CD34+ Cell Dose 
 
Table.3 
 
 
CD34+ Cell Dose and PBSC Engraftment 
 
Table.4 
 
CD 34+cell dose/Kg 
Recipient Body Weight 
Neutrophil Engraftment 
 in Median on Day 
Platelet Engraftment 
in Median on Day 
<  2.5 × 106 
 
18.5 
(16&21)* 
24.5 
(19& 30) 
2.5 – 4.9 × 106  11 
(4-13) 
15 
(11-46) 
5.00 – 7.8 × 106 11 
(10-14) 
13 
(12-19) 
> 7.8× 106 14.5 
(12-15) 
17 
(10-23) 
*Range 
 
 
 In our study patients who received < 2.5 × 106 CD 34+cell dose/Kg recipient 
body weight were achieved neutrophil and platelet engraftment in median on 
day 18.5 and 24.5 respectively. 
0
5
10
15
20
<2.5 2.5-4.9 5-7.8 >7.8
CD 34+CELL DOSE CD34+ Cell 
Dose× 106/Kg 
Frequency Percent 
<2.5 2 7.0 
2.5-4.9 17 56.0 
5-7.8 5 17.0 
>7.8 6 20.0 
Total 30 100.0 
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 Patients who received CD 34+cell dose between 2.5 and 4.9 × 106 cells/Kg 
were achieved neutrophil and platelet engraftment in median on day 11 and 
15 respectively. 
 Patients who received CD 34+cell dose between 5 and 7.8 × 106 cells/Kg 
were achieved neutrophil and platelet engraftment in median on day 11 and 
13 respectively. 
 Patients who received CD 34+cell dose >7.8 × 106 cells/Kg were achieved 
neutrophil and platelet engraftment in median on day 14.5 and 17 
respectively. (Table3,4) 
 
3. AUTOLOGOUS VS. ALLOGENEIC 
 
Frequency Distribution of PBSCT Type 
 
Table.5 
 
 
0
10
20
Auto
Allo
19
11
PBSCT TYPE
PBSCT 
Type 
Frequenc
y 
Percent 
Autologous 19 63.3 
Allogenic 11 36.7 
Total 30 100.0 
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PBSCT Type and Engraftment 
Table.6 
 
PBSCT Type Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Autologous 11 
  (4-13)* 
15 
(11-46) 
Allogenic  14 
(11-21) 
18 
(10-30) 
*Range 
 
 In our study patients who received autologous PBSCT achieved neutrophil and 
platelet engraftment in median on day 11 and 15 respectively. 
 Patients who received allogenic PBSCT were achieved neutrophil and platelet 
engraftment in median on day 14 and 18 respectively.(Table5,6) 
 
4. CONDITIONING REGIMEN 
Frequency Distribution of Conditioning Regimen 
Table.7 
 
 
 
0
2
4
6
8
10
12
CONDITIONING REGIMENConditioning 
Regimen 
Frequency Percent 
Melphalan 11 36.7 
LACE 6 20.0 
CBV 1 3.3 
Bu Cy 8 26.7 
Cy TBI 2 6.7 
Bu Flu 1 3.3 
Bu Cy Flu 1 3.3 
Total 30 100.0 
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Conditioning Regimen and Engraftment 
Table.8 
*Range 
 
Myeloablative Conditioning regimen 
 Patients who received melphalan (200mg) were achieved neutrophil and 
platelet engraftment in median on day 10 and 13 respectively. 
 Patients who received LACE were achieved neutrophil and platelet 
engraftment in median on day 10.5 and 17.5 respectively, one patient with 
CBV were achieved on day 11 and 13, patients with Bu Cy achieved 
neutrophil and platelet engraftment in median on day 13.5 and 15 
respectively. 
Myeloablative 
Conditioning 
regimen 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Melphalan (200 mg) 10 
(4-12)* 
13 
(11-13) 
LACE 10.5 
(9-16) 
17.5 
(16-46) 
CBV 11 13 
Bu Cy 13.5 
(11-16) 
15 
(13-23) 
Cy-TBI 16.5 
(12 & 21) 
24 
(18 & 30) 
Reduced Intensity  
Conditioning 
regimen 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Bu Flu 14 day 10 day 
Bu Cy Flu 14 day     12 day 
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 Patients who received Cy-TBI were achieved neutrophil and platelet 
engraftment in median on day 16.5 and 24 respectively. (Table.4) 
Reduced intensity conditioning regimen 
 Patients who received Bu Flu and Bu Cy Flu regimen were achieved 
neutrophil engraftment in median on day 14 and platelet engraftment in 
median on day 10 and 12 respectively. (Table.7,8) 
 
5. HLA MATCH 
Frequency Distribution of HLA Match  
Table.9 
 
 
HLA match and Engraftment 
Table.10 
HLA Match Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
10/10 
 
21# 30# 
6/6 
 
14 
(11-16)* 
18 
(10-23) 
3/6 
 
14# 12# 
#Single patient with neutrophil and platelet engraftment day achieved *Range 
0
2
4
6
8
10
Ten/Ten
Six/Six
Three/Six
HLA MATCH
HLA 
Match 
Frequency Percent 
Ten/Ten 1 3.3 
Six/Six 9 30.0 
Three/Six 1 3.3 
Total 30 100.0 
100 
 
  Among patients who received allogeneic PBSCT (n=11), one 
patient with 10/10 HLA match achieved neutrophil engraftment on day 21 
and platelet engraftment on day 30. 
 Patients who received 6/6 HLA matched PBSCT achieved neutrophil   and 
platelet engraftment in median on day 14 and 18 respectively. 
 One patient who received 3/6 HLA matched PBSCT achieved neutrophil 
engraftment on day 14 and platelet engraftment on day 12.(Table.9,10) 
 
6. BLOOD GROUP MATCH 
Frequency Distribution of Blood Group Match 
 
Table.11 
 
 
0
1
2
3
4
5
6
ABO
Compatible
Major
Incompatible
Minor
Incompatible
Bidirectional
BLOOD GROUP MATCH
Blood Group 
Match 
Frequency Percent 
ABO 
Compatible 
5 16.7 
Major 
Incompatible 
3 10.0 
Minor 
Incompatible 
1 3.3 
Bidirectional 2 6.7 
Total 30 100.0 
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Blood Group Match and Engraftment 
Table.12 
 
ABO Blood Group 
Match 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
ABO compatible 15 
(12-21)* 
19 
(10-30) 
Major Incompatible 14 
(12-15) 
18 
(12-13) 
Minor Incompatible 16 
 
19 
 
Bidirectional 13 
(12& 14) 
12.5 
(12& 13) 
*Range 
 
 
 
 Patients who received ABO compatible PBSCT achieved neutrophil and 
platelet engraftment in median on day 15 and 19 respectively. 
 Patients who received major incompatible PBSCT achieved neutrophil and 
platelet engraftment in median on day 14 and 18 respectively. 
 Patient who received minor incompatible PBSCT achieved neutrophil and 
platelet engraftment on day 16 and 19 respectively. 
 Patients who received bi-directional PBSCT achieved neutrophil and platelet 
engraftment in median on day 13 and 12.5 respectively.(Table.11,12) 
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7. AGE  
Frequency Distribution of Age Group 
Table.13 
 
Age and Engraftment 
Table.14 
 
Age in Years Neutrophil Engraftment 
In Median on Day 
Platelet Engraftment 
In Median on Day 
<20 12 
(10-16)* 
15 
(12-46) 
20-29 13 
(10-21) 
17 
(12-30) 
30-39 14 
(13-15) 
15 
(10-23) 
40-49 - - 
50-59 10 
(4-12) 
13.5 
(11-17) 
>60 11 15.5 
(12,19) 
*Range 
 
 In our study patients in the age group <20 years were achieved neutrophil and 
platelet engraftment in median on day 12 and 15 respectively. 
 Patients in the age group 20-29 years were achieved neutrophil and platelet 
engraftment in median on day 13 and 17 respectively. 
10
5
3
0
10
2
0
2
4
6
8
10
12
< 20 20-29 30-39 40-49 50-59 ≥ 60
AGEAge Group 
(Years)  
Frequency Percent 
< 20 10 33.3 
20-29 5 16.7 
30-39 3 10.0 
40-49 0 .0 
50-59 10 33.3 
≥ 60 2 6.7 
Total 30 100.0 
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 Patients in the age group 30-39 years were achieved neutrophil and platelet 
engraftment in median on day 14 and 15 respectively. 
 Patients in the age group 50-59 years were achieved neutrophil and platelet 
engraftment in median on day 10 and 13.5 respectively. 
 Patients in the age group >60 years were achieved neutrophil and platelet 
engraftment in median on day 11 and 15.5 respectively.(Table.13,14) 
 
8. DMSO CRYOPRESERVATION 
Frequency Distribution of DMSO Cryopreservation 
Table.15 
 
DMSO Cryopreservation and Engraftment 
Table.16 
 
DMSO Cryo Preservation 
7.5% Final Concentration 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
YES 11 
(9-13)* 
15 
(11-46) 
NO 12 
(4-21) 
15 
(12-30) 
*Range 
 
 
0
10
20
30
Yes No
DMSO CRYOPRESERVATIONDMSO CRYO 
PRESERVATION 
Frequency Percent 
Yes 9 30.0 
No 21 70.0 
Total 30 100.0 
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 Patients who received DMSO Cryo preserved and thawed PBSC graft 
infusion were achieved neutrophil and platelet engraftment in median on day 
11 and 15 respectively. 
 Patients who received fresh (<48 hrs) PBSC graft without DMSO Cryo 
preservation and thawing were achieved neutrophil and platelet engraftment 
in median on day 12 and 15 respectively.(Table.15,16) 
 
9. SEX 
 
Frequency Distribution of Sex 
Table.17 
       
 
 
Sex and Engraftment 
Table.18 
Sex  Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Male 12 
(10-21)* 
11 
(4-16) 
Female 27 
(10-46) 
15 
(11-23) 
*Range 
 
 
15 15
Male Female
0
10
20
Sex SEX Frequency Percent 
Male 15 50.0 
Female 15 50.0 
Total 30 100.0 
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 In our study male gender achieved neutrophil and platelet engraftment in 
median on day 12 and 11 respectively. 
 Female gender achieved neutrophil and platelet engraftment in median on day 
27 and 15 respectively.(Table.17,18) 
 
10. PREVIOUS RADIOTHERAPY  
 
Frequency Distribution of Previous Radiotherapy 
 
Table.19 
 
Previous Radiotherapy  
Table.20 
Prior Radiotherapy  
 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Yes 10.5 
(10-12) 
13.5 
(12-18) 
No 12 
(4-21) 
15.5 
(12-46) 
*Range 
 
 In our study 10 patients received prior radiotherapy dose ranging from 20-
60 CGY was achieved neutrophil and platelet engraftment in median on 
day 10.5 and 13.5 respectively. 
Prior 
Radiotherapy 
Frequency Percent 
Yes 10 33.0 
No 20 67.0 
Total 30 100.0 
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 20 patients was achieved neutrophil and platelet engraftment in median on 
day 12 and 15.5 respectively without any prior radiotherapy. (Table.19,20) 
 In our study due to large number of different drugs administered at 
different doses with various combinations we unable to group and find 
significant influence of chemotherapy regimen on PBSC engraftment. 
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DISCUSSION 
1. DISEASE AND PBSC ENGRAFTMENT 
In our study among hematological malignancies, MM patients achieve 
rapid neutrophil and platelet engraftment than lymphoma and 
leukemia.(Table.21) 
Similarly Thissaiane et al in their study on autologous and allogeneic 
PBSCT in 65 patients with hematological malignancies revealed rapid 
engraftment of neutrophil s and platelets in MM patients than lymphoma and 
leukemia.158 (Table.22) 
Present study (Table.21) 
 
Diagnosis Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Multiple Myeloma 10 
 (4-12)* 
13 
(11-19) 
Lymphoma 
(HL,NHL) 
11 
(13-46) 
16.5 
(13-46) 
Leukemia 
(ALL,AML,CML) 
14 
(12-21) 
25 
(10-30) 
*Range 
 
 
Thissaiane et al 158 (Table.22) 
 
Diagnosis Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Multiple Myeloma 10 
 
11 
Lymphoma 
(HL,NHL) 
11 13 
Leukemia 
(ALL,AML,CML) 
18 21 
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In concordance with our study, M. J. Watts et al in their study on 20 
patients who underwent autologous PBSCT found that Multiple Myeloma 
patients had earlier platelet engraftment than Lymphoma patients. 159 
In our study among 30 cases of hematological malignancies, 
Leukemic patients achieved delayed neutrophil and platelet engraftment than 
MM and lymphoma. 
J. Reiffers et al in their study on 118 patients with hematological 
malignancies found AML patients achieved delayed engraftment than other 
malignancy.160 
 Shirong Wang et al in their study found that in each diagnostic 
subgroup, a stronger correlation between CD34+ cell dose and engraftment 
was seen in patients with MM and NHL. 162Similarly, in our study majority 
(8 out of 11) of MM patients received higher CD34+ cell dose ranging from 
5.3 to 11.4 × 106, which could be the possible reason for faster PBSC 
engraftment. 
In our study all MM patients had received autologous PBSCT. This 
could be another reason for faster engraftment in these group patients. This 
is similar to the study by Bensinger W et al on MM patients on whom 
autologous haematopoietic stem cell transplant yielded faster engraftment.166 
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2. DOSE AND PBSC ENGRAFTMENT 
In our study all patients received 98-100% viable CD 34+ cells and 
those who received graft size ranging from 2.5 – 4.9 × 106 cells/kg achieved 
rapid neutrophil engraftment. However, with regard to the rapid platelet 
engraftment, the graft size infused was 5.0- 7.8× 106 cells/kg. 
 When the graft size was < 2.50 × 106 the neutrophil and platelet 
engraftment was delayed.(Table.23) 
Present study (Table.23) 
 
CD 34+cell dose/Kg 
Recipient body weight 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
<  2.5 × 106 
 
18.5 
(16&21)* 
24.5 
(19& 30) 
2.5 – 4.9 × 106  11 
(4-13) 
15 
(11-46) 
5.00 – 7.8 × 106 11 
(10-14) 
13 
(12-19) 
> 7.8× 106 14.5 
(12-15) 
17 
(10-23) 
     *Range 
      Table.24 
 
Author/Reference CD 34+cell dose Neutrophil 
Engraftment 
( Median Day) 
Platelet 
Engraftment 
(Median Day) 
 
Attilio  
Oliveri et al136 
 
<  2.5 × 106 11 17 
2.5 – 4.9 × 106  11 13 
5.00 – 7.8 × 106 11 12 
> 7.8× 106 
 
10 11 
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Similarly Attilio Oliveri et al in their study on 80 patients with 
hematological malignancy undergoing autologous PBSCT revealed that a 
graft size ranging from 2.5 – 4.9 × 106 cells/kg is safe for complete stable 
and rapid neutrophil engraftment. In the same study, they also found out that 
CD 34+ cell number of 5.0 - 7.8× 106 is the optimal number for obtaining 
rapid platelet recovery.  Further, they also found out that infusion of CD 34+ 
cell number exceeding the threshold of 7.8× 106 cells/kg is not advantageous. 
136,145-147(Table 24) 
However, Charles H. Weaver et al suggested that there is a 
correlation between CD 34+ cell dose of more than 5.0-7.50 × 106 and 
rapidity of engraftment of neutrophil s and platelets.191 (Table.25) 
 
Table.25 
 
Author/Reference CD 34+cell dose 
 
Neutrophil  
Engraftment 
(Median Day) 
Platelet 
Engraftment 
(Median Day) 
Charles H.Weaver191 
 
(Autologous PBSCT) 
0.5-2.5 × 106 11 12 
2.5-5.0 × 106 10 11 
5.0-7.50 × 106 10 11 
7.5-10 × 106 9 10 
10-12.5 × 106 9 10 
>12.5 × 106 8 8 
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Similarly, Nicolas Ketterer et al in their study on 168 patients with 
hematological malignancy undergoing autologous PBSCT, suggested that 
reinfusion of  ≥ 15 × 106 cells further shortens haematopoieticengraftment.192 
Table.26 
 
Author/Reference CD 34+cell dose 
(Median) 
Neutrophil 
Engraftment 
(Median Day) 
Platelet 
Engraftment 
(Median Day) 
Nicolas 
Ketterer et al. 192 
(Autologous PBSCT) 
≤ 2.5 × 106 12 14 
2.5 - 15 × 106 11 10 
≥ 15 × 106 10 8 
 
Similarly, Bender JG et al and Tricot G et al in their studies stated 
that higher administered doses of CD34+ cells increase the speed of 
engraftment for both neutrophils and platelets, especially in heavily pretreated 
patients.193,194 
Similarly, W Bensinger et al in their study on 243 patients with 
hematological and non hematological malignancy undergoing autologous 
PBSCT concluded that CD 34+ cell dose is an important predictor of 
engraftment kinetics after PBSC transplant regardless of disease or 
mobilization technique.195 
Heimfeld S et al and Zaucha JM et al stated that however, survival 
benefits are controversial because studies of adult or pediatric patients who 
received allogeneic HPC (A) transplants from sibling donors for ablative 
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therapy show that very high CD34+ cell doses (>8× 106/kg) were associated 
with increased morbidity resulting from chronic GVHD, a common cause of 
severe morbidity and mortality after allogeneic transplantation and with no 
improvement in survival.154, 156,165 
Similarly H.E.Johnsen et al in their study found that the CD 34+ 
cell dose is the only significant factor that affects the speed of neutrophil and 
platelet engraftment. They also concluded that the quality assessment of 
autografts have been fulfilled by enumerating CD34+ cell subset with flow 
cytometry.196 
Similarly S Heimfeld et al also in their study found that the dose of 
CD34+ cells infused is the only significant factor that affects neutrophil and 
platelet engraftment.141 
Rusten LS, Lyman SD, Veiby OP et al found that in case of 
autologous PBSC transplantation, successful neutrophil  and platelet 
engraftment occurred for all patients with advanced stage or poor-prognosis 
malignant lymphoma who received >2.5 × 106 CD34+ cells/kg in patients. In 
their study, neutrophil engraftment took >2 weeks and platelet counts of 
20,000/μL were not achieved until a median of 31 days in patients receiving 
fewer <2.5 × 106 CD34+ cells.143 
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3. AUTOLOGOUS VS. ALLOGENIC 
In our study patients who underwent autologous PBSCT achieved 
rapid neutrophil and platelet engraftment in median on day 11 and 15 
respectively than those who underwent allogeneic PBSCT in median on 
day14 and 18. (Table27) 
 These findings were similar to the study done by Thissiane et al 
who found faster neutrophil and platelet engraftment in autologous PBSCT 
than allogeneic PBSCT.158 (Table28) 
Present study (Table.27) 
 
Source (AT/AL) Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Autologous 11 
  (4-13)* 
15 
(11-46) 
Allogeniec  14 
(11-21) 
18 
(10-30) 
*Range 
 
Table.28 
 
Author/Reference Source 
(AT/AL) 
Neutrophil 
Engraftment 
In Median on Day 
Platelet 
Engraftment 
In Median on Day 
Thissiane et al 158 
 
Autologous  
10 
11 
Allogeniec  19 
 
21 
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4. CONDITIONING REGIMEN 
 In our study patients who received melphalan conditioning regimen 
achieved rapid neutrophil and platelet engraftment than others and those who 
received Bu Cy and Cy TBI achieved delayed engraftment. 
In our study 2 patients who had received reduced intensity 
conditioning regimen viz., Bu Flu and Bu Cy Flu (Reduced intensity) 
achieved rapid neutrophil and platelet engraftment than Cy TBI 
(Myeloablative) (Table.29) 
Present study (Table.29) 
*Range 
 
Myeloablative 
Conditioning 
regimen 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Melphalan (200 mg) 10 
(4-12)* 
13 
(11-13) 
LACE 10.5 
(9-16) 
17.5 
(16-46) 
CBV 11 13 
Bu Cy 13.5 
(11-16) 
15 
(13-23) 
Cy-TBI 16.5 
(12 & 21) 
24 
(18 & 30) 
Reduced Intensity  
Conditioning regimen 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Bu Flu 14th  day 10th day 
Bu Cy Flu 14th  day 12th day 
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Similarly, Thissiane et al in their study, found that CBV, Melphalan 
(M200) and Flu Cy shows faster neutrophil and platelet engraftment engraftment 
than others and Cy TBI and Bu Cy achieve delayed engraftment than others.158 
Table.30 
Table.30 
 
Author& 
Reference 
Conditioning 
Regimen 
 
Neutrophil 
Engraftment 
 
Platelet 
Engraftment 
 
 
 
 
 
 
Thissiane et 
al158 
 
Melphalan( 
200mg) 
11 
 
11 
 
FLU,CY 12.50 
 
12.50 
 
BU,CY(120mg) 19.00 
 
19.00 
 
CY 200mg 19.00 
 
19.00 
 
CY,TBI 20 
 
20 
 
BU,CY(200) 23.5 
 
23.5 
 
 
In a study carried out on patients with hematological malignancies, 
J.Reiffers et al found that Bu TBI regimen slows the speed of neutrophil 
engraftment.160 
Bensinger WI et al and Dreger P et al in their studies stated that 
apart from CD34+ dose, additional factors that have been reported to affect 
engraftment after autologous transplantation include the type and extent of 
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previous myelotoxic therapy. They found that engraftment is slower after 
total body irradiation (TBI) or busulfan. 182,162 
 Bensinger W et al in their study stated that patients with MM 
achieve faster engraftment after autologous haematopoietic stem cell 
transplant with prior high dose chemotherapy. This has been widely 
accepted as a standard therapy because of its faster tempo of engraftment.166 
Similarly in our study the finding of rapid engraftment in MM 
patients due to melphalan conditioning regimen could be the fact that all of 
them had received autologous PBSCT.  
5. HLA MATCH 
In our study one patient with 3/6 HLA match achieved rapid 
neutrophil and platelet engraftment and one patient with 10/10 HLA match 
delayed neutrophil and platelet engraftment than others (6/6 HLA matched 
patients) (Table.31) 
Present study (Table.31) 
 
HLA Match Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
10/10 
 
21# 30# 
6/6 
 
14 
(11-16)* 
18 
(10-23) 
3/6 
 
14# 12# 
#Single patient with neutrophil and platelet engraftment day achieved *Range 
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J. Szer et al in their study found that allogeneic PBSC from HLA-
identical siblings enhances the speed of neutrophil s and platelets 
engraftment without detrimental effects on GVHD or survival.151 
Although allogeneic PBSC from HLA-identical siblings augments 
the speed of engraftment of neutrophils and platelets,145 in our study the 
finding of delayed engraftment in 10/10 HLA matched PBSCT could be due 
to the fact that inadequate CD 34+ cell dose of 2.10 × 106 cells/kg was 
given. 
The finding of rapid engraftment in 3/6 HLA matched PBSCT 
could be due to the fact that higher CD 34+ cell dose of 6.3 × 106 cells/kg 
was given. 
This is similar to Pulsipher M A et al  study,  that is  administration 
of higher doses of CD34+ cells from related or unrelated, fully or partially 
matched donors that are given to adults or children is consistently associated 
with more rapid neutrophil  and platelet engraftment. 155,157 
Pulsipher.MA et al and Heimfeld.S et al in their study stated that 
however, because of the generally longer time to neutrophil engraftment and 
especially to platelet engraftment associated with allogeneic transplantation 
and with unrelated donors in comparison with autologous patients, a higher 
HPC (A) dose (at least 4 × 106 CD34+ cells/kg) is preferred.152,154 
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6. BLOOD GROUP MATCH 
In our study, among allogeneic PBSCT (n=11), there is no 
significant difference in the speed of engraftment between ABO compatible 
and incompatible PBSC graft. (Table.32) 
 
Present study (Table.32) 
 
ABO Blood Group 
Match 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
ABO compatible 15 
(12-21)* 
19 
(10-30) 
Major Incompatible 14 
(12-15) 
18 
(12-13) 
Minor Incompatible 16 
 
19 
 
Bidirectional 13 
(12& 14) 
12.5 
(12& 13) 
*Range 
 
Similarly G Stussi et al. in their study on 562 patients with 
allogeneic haematopoietic stem cell transplantation found that ABO 
incompatibility has no influence on neutrophil  and platelet engraftment and 
that only RBC engraftment was delayed (particularly in major ABO 
incompatibility). They also suggested that ABO incompatibility does not 
seem to affect the outcome in most patients of stem cell Transplant. 170 
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7. AGE AND ENGRAFTMENT 
In our study patients in the age group between 50-59 years had 
achieved faster neutrophil and platelet engraftment than others. (Table.33) 
Present study (Table.33) 
 
Age in Years Neutrophil Engraftment 
In Median on Day 
Platelet Engraftment 
In Median on Day 
<20 12 
(10-16)* 
15 
(12-46) 
20-29 13 
(10-21) 
17 
(12-30) 
30-39 14 
(13-15) 
15 
(10-23) 
40-49 
 
- - 
50-59 10 
(4-12) 
13.5 
(11-17) 
>60 11 15.5 
(12,19) 
*Range 
 
Similarly Thissiane et al revealed that PBSC engraftment was more 
rapid in the 50-59 year age group and they found that the reason could be 
due to the associated favorable factors like autologous source of PBSC and 
pretransplant conditioning regimen with melphalan 200 mg and CBV.158 
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Table.34 
 
Similar to Thissiane et al study we found, this could be due to the 
fact that all patients in this group except one patient received autologous 
PBSCT and all received melphalan 200 except two patient who received 
LACE and Bu Cy which were also associated with faster engraftment. 
158(Table34) 
Shaji K. Kumar, et al in their study found that the proportion of 
patients attaining WBC engraftment (as indicated by an ANC >500 for three 
consecutive days) by day 15 was 94% for the elderly group (≥70years) 
compared to 78% for the control group (≤65).  Similarly, the proportion of 
patients achieving a non-transfused platelet count of over 50,000 by day 30 
was similar for both groups (81% and 80% respectively) and they concluded 
that chronologic age alone should not be used to decide on transplant 
eligibility.197 
Author/Reference Age in 
Years 
Neutrophil 
Engraftment 
In Median on Day 
Platelet 
Engraftment 
In Median on Day 
Thissiane et al158 
 
<20 19 21 
20-29 18.5 22 
30-39 17 15 
40-49 15 18.5 
50-59 11 13 
>60 11.5 15 
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8. DMSO CRYO PRESERVATION AND THAWING 
 
In our study, the speed of neutrophil and platelet engraftment 
between two groups of patients, one group who were infused with non-
manipulated PBSC graft and other group who were infused with DMSO 
Cryo preserved and thawed PBSCgraft remain almost same.  
 This finding is not similar to the study done by Cigdem A. 
Akkok,et al,  who had observed delayed PBSC graft engraftment following  
DMSO cryopreservation (10% final concentration) and depletion procedure 
due to DMSO toxicity and cell loss.173 
 
Present studyTable.35 
 
DMSO Cryo Preservation 
and Thawing 
(7.5% Final 
Concentration) 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
YES 11 
(9-13)* 
15 
(11-46) 
NO 12 
(4-21) 
15 
(12-30) 
*Range 
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9. SEX 
In our study male gender achieved faster neutrophil and platelet 
engraftment than female gender. This could be due to the fact that majority 
of male patients received autologous PBSCT compare to female patients. 
 
Present Study Table.36 
 
Sex  Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Male 12 
(10-21)* 
11 
(4-16) 
Female 27 
(10-46) 
15 
(11-23) 
*Range 
 
Similarly Thissiane et al in their study also found that male gender 
achieved faster neutrophil and platelet engraftment than female gender.158  
Table.37 
 
Author/Reference Sex Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Thissiane et al158 
 
Male 13 16 
Female 16 20 
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10. PREVIOUS RADIOTHERAPY  
 
To find out the influence of previous radiotherapy treatment, we 
compared the speed of engraftment in patients with or without previous 
radiotherapy treatment, in which we had observed faster neutrophil and 
platelet engraftment in former than latter. This is unlike the observation 
made by Peter Dreger et al on autologous progenitor cell transplantation, 
who found that previous radiotherapy was associated with lower CD34+ cell 
yield but had no influence on engraftment.164 
In our study out of 19 patients who had undergone autologous 
PBSCT, 10 had received radiotherapy. This could be the possible reason for 
relatively faster engraftment in patients who had received previous 
radiotherapy treatment. (Table.38) 
Present study (Table.38) 
 
Prior Radiotherapy  
 
Neutrophil Engraftment 
 In Median on Day 
Platelet Engraftment 
In Median on Day 
Yes 10.5 
(10-12) 
13.5 
(12-18) 
No 12 
(4-21) 
15.5 
(12-46) 
*Range 
 
 
In our study due to large number of different drugs administered at different 
doses with various combinations we unable to group and find significant 
influence of chemotherapy regimen on PBSC engraftment. 
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 Similarly Peter Dreger et al164 in their study stated that chemotherapy drugs 
administered at different doses with various combinations may give 
contradictory results furthermore confounding factors such as underlying 
disease radiation dose and conditioning regimen may mask the effect of 
chemotherapy.  
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SUMMARY 
In our study on factors influencing the engraftment of peripheral 
blood stem cell transplantation on 30 cases of hematological malignancies 
the following features were observed based on AABB engraftment criteria. 
The relative speed of engraftment was analyzed depending on the median 
and range of values (Neutrophil and platelet engraftment days) obtained 
under each individual factors. 
 
 28out of 30 cases received CD 34 + cell dose of ˃ 2.5 × 106 cells/kg, 
achieved faster neutrophil  and platelet engraftment when compared to the 
remaining 2 cases who had received CD 34+ cell dose of  <2.5x106 cells/kg. 
 
 11 out of 30 cases diagnosed as multiple myeloma achieved faster neutrophil 
and platelet engraftment than other hematological malignancies. All these 11 
cases had received melphalan as their conditioning regimen. 
 
 19 out of 30 cases who had received autologous peripheral blood stem cell 
transplantation achieved faster neutrophil and platelet engraftment than 
allogenic PBSCT. 
 
 2 out of 30 cases who had received Cyclophosphamide+Total body 
irradiation TBI (12 CGy) conditioning regimen achieved delayed neutrophil 
and platelet engraftment. 
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 1 out of 30 cases who had received partially HLA matched PBSC (3/6) graft 
achieved same speed of neutrophil and faster platelet engraftment when 
compared to fully HLA matched graft recipients. This is a case of AML who 
had received CD34+ cell dose of 6.30x106/kg recipient body weight. 
 
 6 out of 11 allogenic cases who had received ABO incompatible allogeneic 
peripheral blood stem cell graft (3 major incompatible, 1 minor incompatible 
and 2 bidirectional) showed no significant influence on the speed of 
engraftment. 
 
 With appropriate conditioning regimen and peripheral blood stem cell graft, 
patients in the age group of 50 to 59 years achieved faster neutrophil and 
platelet engraftment than patients at age group < 50 years and > 59 years. 
 
 When compared to 11 female patients who had received autologous PBSCT 
15 males who had also received autologous PBSCT achieved faster 
neutrophil and platelet engraftment. 
 
 9 out of 30 cases who had received DMSO cryopreserved (7.5 % final 
concentration) and thawed peripheral blood stem cell graft (without DMSO 
depletion) showed no significant variation on speed of neutrophil and 
platelet engraftment when compared the remaining cases who had received 
unmanipulated PBSC graft. 
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 10 out of 30 patients, who had received previous radiotherapy showed no 
significant variation on speed of neutrophil and platelet engraftment when 
compared to other patients who had not received prior radiotherapy. 
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CONCLUSION 
In our study there was a definite correlation between CD34+ cell dose 
and speed of engraftment. Autologous PBSCT showed faster PBSC graft 
engraftment than allogenic PBSCT. The expected speed of engraftment could 
be achieved with higher dose of CD34+ cells even in patients with partial HLA 
match. Among various hematological malignancies multiple myeloma patients 
showed relatively rapid PBSC graft engraftment with autologous PBSC as a 
source. Total body irradiation and chemotherapeutic agent busalphan as a 
conditioning regimen showed relatively slower PBSC engraftment.  
Since early engraftment reduces length of hospital stay, morbidity, 
mortality and cost of this highly expensive treatment, it is imperative to utilize 
all available options to enhance the speed of engraftment.  
In a country like India where there are a few established 
haematopoietic stem cell transplantation centers available, there are many 
patients desperately waiting for their life to be saved by this specialized 
procedure. Hence, successful and faster PBSC graft engraftment is absolutely 
essential.  
However, analysis of factors influencing successful engraftment from 
larger number of PBSCT patients would provide some more relevant 
information in this regard. 
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The Department of Transfusion Medicine, 
The Tamilnadu Dr. M.G.R. Medical University 
No. 69, Anna salai, Chennai – 32 
Title of dissertation: Factors influencing the Engraftment of 
haematopoietic stem cell transplantation in patients with haematological 
malignancy 
 
PROFORMA  
Donor or Patient ID: ___________ 
Patient/Donor Name: ___________________________IP NO: ___________ 
Age: ____________ Sex: _____________________ Weight:_______________ 
Address:_________________________________________________________
____________________________________________________________ 
Phone no: ______________ 
Blood group:  
1. O / A / B / AB / Oh                 
2.  Rh: Positive/Negative 
Diagnosis:   ____________________________________________________   
  
Associated Medical Illness: _______________________________________ 
 
Previous medical illness and treatment history: ________________________ 
_______________________________________________________________ 
 
Donor status: 
1. Identical twin (syngeneic)____________________________________ 
2. Sibling__________________________________________________ 
3. Unrelated donor(allogenic)___________________________________  
4. patient’s own (autologous)___________________________________________ 
Peripheral mobilising growth factor: 
1. Type 
2. Schedule 
3. Dose 
Stem cell collection (CD34+ cells) per apheresis: _______________ 
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Type of Chemotherapy regimen /Total body irradiation: 
      1.    Reduced intensity 
      2.    Myeloablative 
 
Degree of HLA Match with patient:  _________________________________                                            
Type of peripheral blood stem cell transplantation: 
1. Allogenic  
2. Autologous 
Dose of CD34+ cells at the time of Transplantation____________________ 
Hematopoietic recovery after stem cell Transplantation  
 
o Absolute neutrophil count __________________ 
o Platelet count____________________________ 
o Total WBC count_________________________ 
o RBC count______________________________ 
o Note: 
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PATIENT& DONOR INFORMATION SHEET 
  
Factors Influencing the Engaftment of Haematopoietic Stem Cell 
Transplantation in Patients with Haematological Malignancy 
 
Haematopoietic stem cell (HPC) transplantation remains the only curative 
option for many haematopoietic malignancies. The haematopoietic stem cells 
required for this procedure are usually obtained from the bone marrow or 
peripheral blood. Currently, the majority of procedures for procurement of 
haematopoietic progenitor cells are performed by peripheral blood apheresis 
collection.  
The ultimate aim of this observational study is to find out the favorable 
and unfavorable factors influencing the outcome of the hematopoietic stem cell 
transplantation in patients with haematological malignancy. Based upon the 
observation in our study in comparison to other studies, suggestions to 
overcome the unfavorable factors for successful hematopoietic stem cell 
transplantation would be given.  
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Consent Form 
 
The Department of Transfusion Medicine, 
The Tamilnadu Dr. M.G.R. Medical University 
No. 69, Anna salai, Chennai – 32 
Title of dissertation: Factors influencing the Engraftment of 
haematopoietic stem cell transplantation in patients with haematological 
malignancy. 
 
I confirm that I read and understood the information about the above research 
study dated ______________ and I had chance to ask the questions. 
My participation in this study is voluntary and I know that I am free to 
withdraw from the study at any time, without giving any reason and without 
affecting my legal rights. 
I agree to this access. I know that my identification or any details will not be 
revealed to third persons or published. 
I agree not to restrict or interfere with any data or results that are obtained from 
this study. 
I agree to participate in this research study for the above listed purpose. 
 
 
 
Donor’s name                    : 
Signature                            :                                                              Date    : 
Signature of the person 
Who obtains consent          :                                                              Date    : 
Donor ID Number              : 
DIAGNOSIS AT/AL HLA MATCH BLOOD GROUP MATCH RBC DEPLETION CO MORBIDITY CONDITIONING REGIMEN DISEASE STATUS AGE SEX WEIGHT RELAPSE CD34 CELL VIABILITY CD34 CELL DOSE(×106/Kg)  NEUTROPHIL ENGRAFTMENT DAY PLATELET ENGRAFTMENT DAY
ALL AL ten/ten ABO compatible No Bil Femur AVN CY T BI CR 26 M 91 Nil 99.00 2.10 21 30
HL (IIB)(NS) AL six/six Minor incompatible Yes Pericardial effusion LACE CR 21 F 78 Nil 100.00 2.20 16 19
HL (NS) AT NA NA No Hard of Hearing BU-CY CR 30 M 56 Nil 99.00 2.50 13 15
HL (III) AT NA NA No Nil LACE CR 22 M 71 Nil 100.00 2.58 10 18
NLPHL AT NA NA No Nil LACE CR 12 M 43 Nil 99.50 2.59 11 46
PCL AT NA NA No IHD,DM,HT,CCF,HyT Mel CR 51 F 60 Nil 99.00 2.60 11 13
ALL AL six/six Major incompatible Yes Nil Cy-TBI CR 17 F 71 1 100.00 2.90 12 18
AML AL six/six ABO compatible No Nil CY,BU CR 13 F 39 Nil 98.00 3.10 11 15
MM (IIIA) AT NA NA No Type 2DM Mel CR 53 M 71 Nil 100.00 3.14 10 14
NHL (III) AT NA NA No Nil LACE CR 14 F 38 Nil 100.00 3.18 10 15
HL (IIA) AT NA NA No Nil LACE CR 28 M 67 Nil 100.00 3.50 12 12
MM (IIIA) AT NA NA No DM Type 2,HT Mel CR 51 M 85 Nil 100.00 3.59 12 14
MM (IIIA) AT NA NA No Nil Mel PR 25 F 46 Nil 100.00 3.60 10 13
HL (III A) AT NA NA No Nil CBVC CR 13 F 74 Nil 99.00 3.84 11 13
MM (IIIA) AT NA NA No Nil Mel CR 52 F 61 Nil 100.00 4.11 10 11
MM (IIIA) AT NA NA No Nil Mel CR 52 F 55 Nil 100.00 4.60 10 13
MM (IIIA) AT NA NA No Nil Mel CR 62 M 85 Nil 100.00 4.70 11 12
MM (IIIA) AT NA NA No DM,ATT Mel CR 57 F 54 Nil 100.00 4.82 4 17
MCL (IV) AT NA NA No Nil LACE CR 53 F 53 Nil 100.00 4.88 9 17
CLL AL six/six ABO compatible No Nil * CR 51 M 67 Nil 98.00 5.00 * *
MM (IIIA) AT NA NA No Nil Mel CR 55 M 66 Nil 100.00 5.20 11 16
CML AL six/six Bidirectional Yes Nil BU-CY CR 53 M 61 Nil 100.00 5.30 12 13
MM (IIIA) AT NA NA No Nil Mel CR 58 M 72 Nil 100.00 5.50 10 12
MM (IIIA) AT NA NA No IHD,DM,HT,CAD,COPD Mel CR 62 M 76 Nil 98.50 5.59 11 19
AML AL three/six Major incompatible Yes Nil BUCYFLU CR 18 F 71 2 100.00 6.30 14 12
AML AL six/six ABO compatible No Nil BU-CY CR 15 F 54 Nil 98.00 8.40 15 23
APML AT NA NA No HBSAg Positive CY,BU CR 12 M 45 Nil 99.00 8.80 12 15
CML AL six/six ABO compatible No HbsAg+ BU-FLU CR 31 M 55 Nil 100.00 9.00 14 10
AML AL six/six ABO compatible No HCV+ BU-CY PR 10 F 46 Nil 99.20 9.20 16 19
AML AL six/six Bidirectional Yes Nil BU-CY CR 20 F 66 Nil 100.00 10.00 14 12
AML AL six/six Major incompatible Yes Nil BU-CY CR 32 M 50 3 100.00 11.14 15 23
AT=Autologous CR=Complete Remission
AL=alloganeic PR=Partial Remission
